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Abstract 
The unpredictability and complexity of biological systems limit the development 
of economically efficient bio-based production processes that rely on renewable 
carbon sources and are essential for biosustainability and environmental 
protection. Synthetic biology (synbio) aims at making biology easier to engineer 
and addresses these challenges. 
The ability to systematically construct, modify and tune biological systems from 
fully characterized biological components, or parts, is crucial to the success of 
synbio projects. This thesis aims at contributing to standardization and part 
sharing with the development and improvement of DNA editing strategies, 
compatible with other DNA assembly methodologies, genome engineering and, 
eventually, automation processes.  
Expanding and optimizing the synbio toolkit has important applications in 
pathway optimization for metabolic engineering, design and characterization of 
gene circuits, synthesis of whole genomes and natural product discovery. In line 
with this, it is also described in this thesis how discovery of new cytochromes 
P450 (CYPs) from marine bacteria could benefit industrial processes. 
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Dansk resumé 
Uforudsigeligheden og kompleksiteten af biologiske systemer begrænser 
udviklingen af økonomisk effektive biobaserede produktionsprocesser, og disse 
er afhængige af vedvarende kulstofkilder og er afgørende for biobæredygtighed 
og miljøbeskyttelse. Syntetisk biologi (synbio)  har til formål at muliggøre og 
standardisere udnyttelse og design af nye biologiske systemer. 
Evnen til systematisk at konstruere, modificere og optimere biologiske systemer 
fra velkarakteriserede biologiske komponenter er afgørende for succes i synbio 
projekter. Denne afhandling bidrager til at standardisere og forbedre  DNA 
redigeringsteknologier til modelbakterien Escherichia coli - og i sidste ende 
muliggøre automatisering af sådanne processer. 
Udvidelse og optimering af en synbio værktøjskasse er desuden vigtig for 
biosynteseoptimering, design af cellefabrikker og opdagelsen af nye naturstoffer. 
I tråd med dette undersøges marine bakteriers potentiale for opdagelsen af nye 
enzymer til anvendelse i  industrielle processer. 
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Introduction and thesis overview 
To reduce the world’s dependency on oil, our society has to change from a fossil-
based industry to more biosustainable production strategies. Environmental 
protection and biosustainability are currently heavily dependent on economically 
efficient bio-based production processes from renewable carbon sources1. The 
problem with this approach is that biological systems are complex and 
unpredictable. Synthetic biology (synbio) addresses these challenges. 
One definition of synbio is the attempt to make biology easier to engineer by 
understanding and making sense of composition and rational logic of biological 
systems2–4. Its potential was recognized in 2012 when synbio was included in the 
World Economic Forum’s Global Agenda Council on Emerging Technologies as 
one of the top 10 emerging technologies 
(http://www.chemistryviews.org/details/news/1478647/The_2012_Top_10_Emer
ging_Technologies.html). Important accomplishments and the available synbio 
toolkit have been reviewed5–7. 
The vision of synbio relies on key concepts such as multidisciplinarity and 
standardization. The ultimate goal of the field is the targeted design and rational 
construction of complex biological systems for industrial purposes. 
In 1988, Richard Feynman said: “What I cannot create, I do not understand”. This 
statement has become a foundational concept of synbio. The success of future 
synbio and biotechnology will depend on the ability to systematically construct, 
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modify and tune biological systems from fully characterized biological 
components, or parts8. Parts are defined as DNA fragments that perform a 
specific function in a genetic circuit and an extended catalogue of well-studied 
biological parts is currently lacking. Bringing people together in a highly 
dynamic synbio community for the common goal of gathering knowledge in a 
systematic way is one of the adopted strategies to overcome this limitation. 
Several groups are currently involved in shaping the field such as funding 
agencies, research centres, companies or amateur “biohackers” like the 
International Genetically Engineered Machine (iGEM) student competition or the 
do-it-yourself biology (DIYBIO) movement9,10.  
When starting a new synbio project, there are typically at least four parameters to 
consider when choosing the molecular tools and the cellular container that 
accommodates and executes the necessary cellular functions (the chassis), for 
production of specific proteins, chemicals and genetic circuits11: 
a) Chassis stability and growth conditions; 
b) Available DNA editing technologies; 
c) Ability to manipulate homologous and heterologous biosynthetic pathways 
(e.g. promoters and vectors); 
d) Software tools for assisted planning and debugging. 
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Thesis outline 
 
This thesis focuses on several important tools used in synbio. For simplification 
purposes, a glossary with the synbio concepts used throughout the thesis is 
provided (on page 4). The thesis is focused mainly on three of the above-
mentioned parameters: chassis selection, available DNA editing strategies and 
software tools. Additionally, the most recent advances in DNA synthesis and 
sequencing, as well as examples of some of the most successful applications 
using synbio tools are briefly discussed. The need for standardization and more 
efficient DNA assembly technologies fuelled the work described in three 
publications: Paper I - Accurate DNA assembly and genome engineering with 
optimized uracil excision cloning; Paper II – Uracil excision for assembly of 
complex pathways; Paper III – SEVA linkers: a versatile and automatable DNA 
backbone exchange standard for synthetic biology. Paper IV - Marine Bacterial 
Cytochromes P450 and their potential in biotech is a good example on how 
powerful in silico tools can be for new enzyme discovery with industrial 
applications. Finally, concluding remarks and future perspectives are described, 
summarizing the contribution of this project to the synbio field. 
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1. Glossary – Important synbio concepts 
Abstraction - the idea that complex biological functions can be organized across 
levels and conceptually separated from the original sequence context; 
BioBricks - standardized biological components; 
Chassis - cellular container that accommodates and executes the required cellular 
functions; 
Combinatorial - assembly with any number of parts at any number of defined 
positions; 
Destination vector - the vector into which the DNA from entry vector will be 
sub-cloned; 
Entry vector – the vector that carries the DNA segment to be transferred to 
destination vector; 
Forbidden sites – restriction sites recognized by restriction enzymes that cannot 
be present in parts to be assembled; 
Genetic circuit - functional clusters of genes that impact each other's expression 
Modularity – the ability of a component or system to function in a context-
independent way; 
Operon - group of genes under the control of a single promoter or multiple 
promoters; 
Orthogonality – independent behaviour of biological parts; 
Standardization – process of developing or implementing technical standards 
(fully characterized parts); 
Part - DNA sequence defined by a specific function it performs in a genetic 
circuit; 
Pathway – group of genes or operons, which may perform related functions; 
Transcriptional units - DNA sequences that encode a single RNA molecule 
together with sequences required for its transcription - usually promoter, open 
reading frame and terminator. 
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2. The pre-synbio Era: History of recombinant DNA 
engineering 
The elucidation of the molecular structure of DNA in 1953 by James Watson, 
Francis Crick and Rosalin Franklin was an important first step in the history of 
recombinant DNA engineering. Since then, several achievements have joined the 
hall of fame in DNA engineering - from oligonucleotide and gene synthesis to the 
discovery of restriction enzymes (Figure 1). These tools created the basis for the 
first successful recombinant DNA engineering12–15 and for the first heterologously 
expressed gene for production of a recombinant pharmaceutical protein (human 
insulin) in the early 80’s16. 
 
 Figure 1 – Timeline on history of recombinant DNA engineering. 
Less than a decade later, the development of the Polymerase Chain Reaction 
(PCR) was a major breakthrough. The simple and exponential nature of PCR, 
which consists of the combined action of two synthetic oligonucleotides with a 
DNA template strand and a thermophilic DNA polymerase, is a prime example of 
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a human-made innovation that revolutionized molecular biology. PCR simply 
made it easy to work with DNA. Shortly after the advent of PCR, a plethora of 
novel methods for DNA editing were developed. DNA reading and writing 
technologies followed and around the new millennium, commercial gene 
synthesis by Blue Heron Biotechnologies, Inc and Next Generation sequencing 
hit the market. 
Recent major achievements that will transform synbio are related to the 
development of CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic 
Repeats) engineering systems. Just like restriction enzymes, CRISPR is a 
bacterial immune mechanism used by many prokaryotes for protection against 
invading nucleotide sequences17–20. Transformation from a natural immune 
system to a genome engineering tool happened when two independent reports 
demonstrated for the first time that type II CRISPR/Cas9 nucleases (from 
Streptococcus pyogenes) could be programmed using short synthetic guide RNAs 
(gRNAs) for sequence-specific targeting and cleavage in human and mouse 
cells21,22. In the same year (2013), this was shown for bacteria using Cas9 from S. 
pneumoniae23. The ability to reprogram Cas9 to target any sequence, as well as 
the accuracy, efficiency, simplicity and cost of CRISPR/Cas systems turned 
CRISPR/Cas-based genome engineering into the most popular technology 
currently available. In essence, CRISPR is doing to genome engineering, what 
restriction enzymes and PCR did to DNA engineering. 
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Overall, the constant innovation and improvement of most of these technologies 
help build the foundations of synbio. 
3. The value of standardization and part sharing 
Biological systems are generally complex and unpredictable, which makes them 
difficult to engineer. Furthermore, combinatorial studies can easily become too 
laborious or even unfeasible to perform when assembly of hundreds of parts is 
required. Finally, increased complexity frequently comes with a price tag. These 
fundamental challenges were a call to action for development of more efficient 
characterization strategies and open sharing of information and parts, which 
would be beneficial for the whole scientific community24,25. There is general 
agreement that the success of building processes depends on more efficient and 
design-driven use of predictable standards. 
The engineering of biology needs standardization since it enables selection and 
recycling of required DNA elements from a vast list of previously characterized 
parts, as well as part exchange between different users. With this perception came 
the attempt to establish large registries of parts26.  
The NOMAD (Nucleic acid Ordered Assembly with Directionality) was probably 
the first attempt to standardize DNA construction and happened 20 years ago27. 
More than a decade later, the Registry of Standard Biological Parts appeared as a 
joint effort involving the International Genetically Engineered Machine (iGEM) 
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student competition (http://www.igem.org) and the BioBricks Foundation28. It is 
still widely used by the scientific community, despite several discrepancies being 
reported in quality and published sequences. The Standard European Vector 
Architecture (SEVA) platform29–31 is yet another large repository of parts that 
includes broad host range origins of replication. Several other repositories were 
then reported like the JBEI-ICEs registry32 or the BIOFAB collection33,34, now 
available in the Addgene repository35 that contains more than 31,000 unique 
plasmids available for the scientific community. More recently, the GenoLIB 
database36 aimed at getting rid of problems regarding ambiguous plasmid 
annotations. 
The open source nature of these repositories is both advantageous and limiting. 
The public accessibility and free sharing of information and parts enables faster, 
cheaper and less laborious experimental design and testing. Standardization goes 
together with simplicity and should be accompanied by as few rules as possible. 
Despite the facilitated sharing process, there are still intellectual property (IP) 
issues and costs for shipping and general operating maintenance. Part sharing can 
have additional drawbacks and users should keep in mind that there might be 
some lack of consistency in parts description and that unpredictable interactions 
between different elements may occur25. In other words, universality and 
orthogonality should not be taken for granted37. 
 9 
Predictability of parts is hence a major challenge for synbio projects. The idea 
that complex biological functions can be organized across different levels and 
conceptually separated from the original sequence context defines the use of 
abstraction in synbio24. Together with powerful software tools and programming 
to achieve automation, abstraction is crucial for the attempt to predict and 
optimize reliable part behaviour10. Additionally, advances in metrology, the 
science of measurement, will increase confidence in part characterization-
associated measurements, contribute to reproducibility between different 
laboratories and, thus, reliable characterization of parts or standardization38. 
Overall, the green, clean and cheap vision of synbio will depend heavily on 
standardization and predictability of standards, which will only be accomplished 
with the development of DNA editing technologies and software tools, as well as 
full characterization and optimization of the host chosen for expression of 
synthetic circuits. 
4. Model cell factories – chassis selection 
In synbio, the chassis is the cellular container (or host) that provides structures to 
accommodate and execute the necessary cellular functions. The choice of chassis 
is thus a crucial step in bio-production of any chemical or protein, since it will 
influence the function and behaviour of genetic elements39,40. The production 
host, or cell factory, should be non-pathogenic, genetically stable and well-
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characterized, be able to survive under the desired process conditions (such as 
specific pH and temperature or low nutrient requirements) and ideally possess a 
catalogue of available engineering tools11. Additionally, one should also consider 
whether the desired metabolic pathway exits or can be reconstructed in that 
particular host41. Several options are currently available for chassis selection10. 
However, two microbial cell factories, Escherichia coli and Saccharomyces 
cerevisiae, have dominated as workhorses in synbio tool development as well as 
bio-production of chemicals or proteins with applications in pharma, food or 
biotech industry. 
4.1. Escherichia coli 
The Gram negative, facultatively anaerobic, rod-shaped bacterium E. coli is by 
far the most widely studied prokaryotic model organism – and in fact probably 
the best studied living organism. While some strains might be pathogenic, most 
E. coli strains are part of the natural flora of the gut of warm-blooded organisms. 
This robust bacterium possesses a number of properties that make it an ideal 
candidate for metabolic engineering and synbio such as fast doubling time, 
metabolic versatility, well-known metabolism and genome, and available genetic 
tools for strain manipulation and engineering10,41–43. Despite being the host of 
choice for development of DNA engineering technologies, non-pathogenic E. 
coli’s fame is due to the considerable amount of generally recognized as safe 
(GRAS) recombinant pharmaceutical proteins that are being produced in this 
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model organism as well as bio-fuels, amino acids, sugar alcohols, diols and 
polymers42. 
Major shortcomings of using E. coli as a chassis include the inability to perform 
post-translational modifications such as glycosylation, common in eukaryotic 
proteins, the susceptibility to phage attacks and production of endotoxins41,44–46. 
4.2. Saccharomyces cerevisiae 
The baker’s yeast is the most intensively studied unicellular eukaryote and the 
first genetically modified organism to be approved for use in food production. As 
bacteria, S. cerevisiae is a fast growing, well-characterized organism with a vast 
array of engineering tools that justify its frequent use47. Besides being tolerant to 
low pH and high sugar and ethanol concentrations, S. cerevisiae shares more 
similarity with higher organisms, in terms of complexity of cellular structure, and 
is able to perform post-translational modifications that are required for production 
of most eukaryotic proteins. Furthermore, the GRAS status of both S. cerevisiae 
and yeast-derived products helped build its reputation as a host of choice48. Apart 
from centuries of use in baking, brewing, wine making and bio-ethanol 
production, this microorganism has proven its value as a cell factory for 
production of amorphadiene, vanillin, polyketides, isoprenoids, steviol 
components and opiates47–49. 
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Synbio tools in yeast are lagging behind the E. coli ones and one major drawback 
when choosing the first chassis is the small number of inducible promoters 
available47,50,51.  
4.3. Alternative chassis 
There is an obvious trade-off between chassis selection and successful expression 
of synthetic systems. When special traits are required for production or specific 
technology development, alternative hosts with attractive peculiarities might be 
advantageous over the established model cell factories. Currently, there is a list of 
organisms that goes from bacteria and yeast to insect and mammalian cells, as 
well as cell-free systems that in specific situations offer advantages to the 
previously described model cell factories52,53. Two of them deserve special 
attention, Bacillus subtilis and Pseudomonas putida, mainly due to their recent 
contributions to the synbio field54. 
The model Gram-positive B. subtilis is also an extensively studied and used 
GRAS organism with a diverse molecular biology toolkit available. Apart from 
rapid and inexpensive growth, the most appealing features of this host are the 
heat-resistance spore formation and secretion of proteins, explaining why it is 
frequently chosen for recombinant protein production55–57. This organism has also 
shown its potential when handling large DNA construct assembly58. Limitations 
on its use are related to plasmid stability and very active proteolytic degradation 
systems10. 
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One example of non-established but emerging chassis is P. putida. It emerged 
some years ago as an alternative to the previously mentioned chassis. This soil 
and plant-root associated, ubiquitous and saprophytic Gram-negative bacteria has 
gained some attention due to its metabolic versatility and tolerance to many 
xenobiotic compounds as well as pH and temperature variations59,60. Its potential 
for applications like industrial biocatalysis, bioplastic production or in situ 
bioremediation resulted in rapid increase in reports with the aim of expanding the 
tools available for P. putida engineering29–31,61. As for all emerging or potential 
chassis, the major shortcomings of choosing P. putida are related to the still 
limited synbio toolkit. 
 
Despite the potential of alternative (established or emerging) chassis, E. coli and 
S. cerevisiae are still the preferred choices. Both systems have advantages and 
limitations in their use and its common to combine them even in simple projects. 
E. coli serves as cloning host, while S. cerevisiae is responsible for production. A 
recent trend has taken advantage of yeast’s homologous recombination and 
ability to handle large DNA fragments, where big-sized constructs are assembled 
in yeast and transferred to E. coli for expression and production62. 
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5. DNA assembly 
Assembly of DNA is at the core of synbio and biotechnology11,63,64. 
Consequently, advances in DNA editing technologies have been game changing 
for most biological research projects63. Tailoring of parts into genes, genes into 
pathways and ultimately whole genomes would not be possible without the tools 
of molecular biology developed over the past half century such as restriction 
enzymes, homologous recombination, PCR and more recently CRISPR/Cas. 
Currently, the steadily decreasing price of synthetic DNA is increasingly allowing 
for outsourcing DNA editing65. However DNA synthesis does not prevent the 
need for DNA assembly (even for gene synthesis companies) and synbio still 
relies on effective methods to facilitate exchange of individual parts and 
minimize de novo design. 
The increased ability to synthetize/PCR amplify different parts stretched our 
boundaries and is allowing for challenging DNA assemblies58,62,66,67. Hence, 
considerable efforts have been devoted to the development of new DNA 
assembly methods or improvement of the existing toolbox to achieve modularity, 
recycling of pre-existing parts and simplicity at a cheaper price and in a less 
laborious fashion63,68–70. Consequently, the growing throughput of assembly 
projects does not call exclusively for new improved DNA assembly technologies 
but also for new software packages that allow researchers to cope with increasing 
complexity and scale71. In vitro (Figure 2A) and in vivo (Figure 2B) DNA 
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assembly technologies are herein reviewed (summarized in Table 1) and grouped 
according to the strategy employed. The software tools that support these DNA 
assembly approaches will be further described and can also be found in Table 1. 
Genome engineering strategies are based on editing of existing sequences instead 
of combining parts together like DNA assembly technologies68. Thus, genome-
based approaches will not be reviewed in this section, except when in 
combination with DNA assembly strategies. 
 
Figure 2 – Schematic representation of (A) in vitro and (B) in vivo five-
fragment DNA assembly of a four-gene pathway (colourful shapes) and 
backbone (black line), and transformation into the host cell (orange shape). 
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Table 1 - DNA assembly tools and supporting software. 
Strategy Mechanism Sequence independency 
Specific 
requirements/ 
comments 
Supporting 
Software 
BioBricks72,73 Type IIP RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
Registry of 
standard 
biological 
parts28; Raven71 
BglBricks74 Type IIP RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
Under 
development 
BioScaffold75 Type IIB RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
- 
Golden 
Gate76,77 
Type IIS 
RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
J578,79 
PSA80 Type IIS RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts; 
attachment tags 
- 
GoldenBraid8
1,82 
Type IIS 
RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
- 
MoClo83 Type IIS RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
Raven71 
mMoClo84 Type IIS RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
- 
GreenGate85 Type IIS RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts; 
methylated sites to 
prevent restriction 
- 
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MASTER86 Type IIM RE  No 
Methylated 
restriction site at 
the ends; 
forbidden sites 
within parts 
- 
SEVA29–31 RE No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
SEVA-DB 
platform31 
iBrick87 RE No 
Homing 
endonucleases 
restriction site at 
the ends 
- 
Gateway®88,89 SSR No λ recombination att sites - 
SIRA90 SSR No 
φC31 
recombination att 
sites 
Under 
development90 
SSRTA91 SSR  
ϕBT1 
recombination 
att sites 
- 
OE-PCR92,93 Overlap Yes Inefficient for long constructs - 
CPEC94,95 Overlap Yes Inefficient for short sequences J5
78,79 
LIC-PCR96 Overlap No 
12 bp overhang 
with no 
predetermined 
dNTP 
- 
SLIC97 Overlap Yes Inefficient for short sequences J5
78,79 
SLiCE98 Overlap Yes Inefficient for short sequences J5
78,79 
Uracil 
excision99–103 Overlap Yes 
ANxT sequence, 
incorporated 
uracil 
PHUSER104,105
AMUSER106 
PLICing107 Overlap Yes 
Phosphotioate 
bonds, iodine 
solution 
- 
In Fusion®108–
110 Overlap Yes 
Inefficient for 
short sequences 
Convert PCR 
Primers Into In-
Fusion ® 
Primers 
website* 
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Gibson 
Assembly111–
113 
Overlap Yes Inefficient for short sequences J5
78,79; Raven71 
LCR114 Bridging oligos Yes 
5’ 
phosphorylation; 
bridging 
oligonucleotides 
Gene2Oligo115 
PaperClip116 Bridging oligos No 
Half clips with 
GCC/GGC at 
5’end; 5’ 
phosphorylation; 
bridging 
oligonucleotides 
- 
 
MODAL117 Mixed No 
45 bp linker 
regions plus 15 bp 
adapter sequences 
R2oDNA 
Designer118 
BASIC119 Mixed No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
R2oDNA 
Designer118 
HVAS120 Mixed No 
λ recombination 
att sites; homing 
endonucleases 
restriction site 
- 
Guye et al121 Mixed No 
λ recombination 
att sites; homing 
endonucleases 
restriction site 
- 
Torella et al122 Mixed No 
Restriction site at 
the ends; 
forbidden sites 
within parts 
- 
 
*http://www.clontech.com/US/Products/Cloning_and_Competent_Cells/Cloning_Kits/xx
clt_onlineToolsLoad.jsp?citemId=http://bioinfo.clontech.com/infusion/convertPcrPrimers
Init.do&xxheight=750 
 
5.1. Restriction enzyme-based approaches 
Restriction enzymes (RE) cut DNA at (or near) a specific recognition site and, 
like CRISPR, originate from bacterial defence systems against invading 
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nucleotide sequences. More than 40 years ago, the discovery of restriction 
digestion and ligation revolutionized the field of molecular biology12; so much 
that, in 1978, a Nobel Prize was jointly awarded to Werner Arber, Dan Nathans 
and Hamilton Smith for the discovery of “restriction enzymes and their 
application to problems in molecular genetics”. Since then, several methods have 
been developed using RE. 
There are four types (type I, II, III and IV) of RE classified based on cleavage 
position, sequence specificity, co-factor requirements and subunit composition. 
Type II RE are a more heterogeneous group that, in general, cut DNA within or 
close to restriction sites, require Mg+ and have only endonuclease activity123. 
They are also the only group used in laboratorial routine DNA cloning and 
analysis. 
The main requirement relies on restriction sites exclusively flanking the parts to 
be joined that are recognized by specific RE. Restriction sites are thus “forbidden 
sites” within the sequences to be assembled. RE-based methods are still popular 
nowadays due to robustness and long use, in spite of the inherent constraints by 
the sequence context (“forbidden sites”) and the ligation step that is generally 
renowned to be inefficient68. 
By today’s criteria, modularity, recycling of parts and standardization become a 
crucial part in complex engineering projects. The first step towards modularity 
was accomplished with the BioBrick standard72,73, where BioBricks refer to 
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standardized biological components. This lego-like concept requires standardized 
restriction sites that compose the so-called prefix (EcoRI XbaI) and suffix (SpeI 
PstI) that flank each BioBrick. Digestion and ligation allows for assembly of two 
parts per reaction. Continuous addition of BioBricks is possible, and several 
enzymes might be used to remove sites, produce compatible ends or adapt to 
different cloning strategies. However, the biggest shortcomings of this approach 
are the presence of scars that might affect gene expression and its limitation in 
terms of multipart assembly72. Improvements to the method towards a more 
flexible setup include the so-called BglBricks74 that introduced a six bp scar 
(using BglII and BamHI) encoding a glycine-serine innocuous peptide linker for 
most protein fusions. Shortly afterwards the BioScaffold75 overcame the issue of 
scars or insertion of additional inserts previously incompatible with the BioBrick 
standard assembly resorting to PrsI, a type IIB RE that cleaves both sides of 
target DNA sequence in both strands. 
Overall, the previously mentioned strategies still require the removal of excessive 
restriction sites from the parts to be joined prior to assembly. Homing 
endonucleases offer an alternative solution to this problem since these RE 
recognize long sequences (12 - 40 bp) with extremely rare restriction sites124,125. 
These sequences are also non-palindromic allowing for directional cloning125. 
Recently, the iBrick standard was developed using two homing endonucleases 
that recognize >18 bp DNA sequences87. Notwithstanding the advantage of 
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enabling assembly of large sized parts, a 21 bp scar is created between each part, 
which might affect gene expression. 
Nowadays, modularity and simplicity are key elements to success in complex 
assembly projects. The Standard European Vector Architecture (SEVA) 
platform29,31 offers a new level of parts standardization with regards to expansion 
of the available toolbox from enteric bacteria to other hosts like P. putida29 or 
Mycobacteria126. It consists of three interchangeable modules: (1) antibiotic 
resistance markers, (2) origins of replication and (3) the cargo, which generally 
contains the genetic elements necessary for the end-application of the cell factory 
(very often a promoter driving expression of a gene), flanked by the rare RE sites 
PacI, SpeI, SwaI, PshAI, FseI, AscI (rare because they recognize a sequence not 
frequently found in natural DNA sequences). This system currently allows for 54 
combinations of nine origins of replications with six antibiotic resistance 
markers31. Recently, the gadget, a fourth module encoding for the hok/sok system 
that ensures killing of cells that lose the plasmid, was included, with the 
additional introduction of a SanDI rare site30. Apart from supporting modularity 
and promoting standardization, the SEVA platform has some limitations related 
to the constraints of restriction enzyme-based assembly. To overcome this 
limitation, the SEVA linker backbone exchange standard (Paper III in this thesis), 
was developed to be compatible with rare cutters but also nicking enzymes.  
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5.1.1. Nicking endonucleases 
Acting usually as homodimers, restriction enzymes perform site-specific double-
stranded breaks via hydrolysis of both phosphodiester bonds of double-stranded 
DNA (dsDNA)127. So-called nicking enzymes (NE), like other RE, recognize 
short specific DNA sequences and cleave DNA at a defined position; however, 
unlike normal REs, NEs cleave only one predetermined DNA strand in the 
dsDNA128. Suggestions that NE are naturally mutated restriction enzymes that do 
not possess dimerization ability might explain their origin129,130. 
The discovery of NE happened almost a decade ago128,131. Nevertheless, the 
limiting number of available NE was an impelling cause that led to protein 
engineering efforts to create new NE130,132. Since then, this group of enzymes has 
been extensively used either in ligation-independent cloning methods or for the 
generation of compatible overhangs that can be coupled with another DNA 
assembly technology133–136. The biggest advantages of these NE-based methods 
when compared to normal RE-based approaches lie in their compatibility with 
other cloning strategies to create compatible overhangs and the fact that nicked 
DNA can endure after ligation or transformation. 
5.1.2. Type IIS restriction enzymes 
The use of RE experienced a renaissance with the type IIS-based methodologies. 
Type IIS RE are a class of endonucleases that cleaves outside of its recognition 
site generating variable overhang sequences76. The biggest advantage of using 
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type IIS RE comes from their ability to assemble multiple DNA fragments in a 
defined linear order, since the same enzyme can generate different overhangs. 
Moreover, the freedom to choose the overhang sequence offers the possibility for 
scarless DNA assembly. Seamless assembly is accomplished by flanking the 
DNA parts with recognition sites in inverse orientation, which are then removed 
during the cleavage process. 
Previously, although not used routinely in cloning, type IIS RE have been used 
for assembling a 32 kb cluster137 or cloning repetitive sequences138,139. Golden 
Gate cloning76,77 has gained popularity because it exploits the advantages of type 
IIS RE-based DNA assembly, particularly with BsaI (Figure 3). Golden Gate 
parts, generated by either DNA synthesis or PCR, are sub-cloned into entry 
vectors, which carry the DNA segment to be transferred, before digested and 
ligated into destination vectors, into which the DNA will be sub-cloned76,77. What 
makes this strategy so simple is that several plasmids can be directly mixed into 
one single tube, together with one single RE that will create different overhangs 
and a DNA ligase that will join all parts. This mixture can be directly transformed 
into a cloning host without additional steps and screening of desired clones is 
accomplished by using the antibiotic to which correct transformants will be 
resistant to. 
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Figure 3 – Overview of Golden Gate cloning. PCR-amplified parts (insert and 
vector) with BsaI-recognition sites (grey arrows) flanking each part in reverse 
orientation are mixed together with BsaI and DNA ligase. BsaI cleavage allows 
the formation of different overhangs (orange and green) that are four bp in length 
and complementary with the corresponding end in the other part (in this case, 
complementary overhangs are represented in the same colour). After restriction 
digestion, the DNA ligase, present in the mixture, ensures complementary 
overhangs are stitch together. This strategy is repeated for several cycles of 
restriction-ligation in a one-tube reaction. Final vectors are not subjected to 
further restriction digestion since they do not possess a BsaI-restriction site. For 
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re-use of parts, inserts are usually cloned into an entry vector first and then mixed 
with a destination vector that possesses a different antibiotic resistance marker. 
 
Golden Gate cloning was described eight years ago and, since then, several 
improvements have been made to the technology. The first appeared with the 
Modular Cloning System (MoClo)83 where a 33 kb construct containing 11 
eukaryotic transcriptional units (DNA sequences that encode a single RNA 
molecule together with sequences required for its transcription - usually 
promoter, open reading frame and terminator) was assembled from 44 modules in 
only three successive cloning steps. It was further extended to a 50 kb construct 
corresponding to 68 DNA fragments and 17 eukaryotic transcriptional units140. 
Mammalian Modular Cloning (mMoClo)84 has also been described, where six 
transcriptional units corresponding to 27 kb and 42 parts were chromosomally 
integrated. The shortcomings of these optimizations are the large number of entry 
and destination vectors. The GoldenBraid standard81 and its optimized version 
GoldenBraid 2.082, other improvements to the Golden Gate cloning, overcome 
this issue with the reduction of the number of required vectors; however, 
additional rounds of assembly are required for larger constructs. Other reports on 
Golden Gate cloning developments have been reported both for yeast and 
plants141–144. 
The Pairwise Selection Assembly (PSA)80 is a related strategy using type IIS RE 
that was published shortly after Golden Gate cloning. The premises are similar to 
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Golden Gate cloning; however, PSA requires the use of two divergently oriented 
non-functional antibiotic resistance markers and the attachment of corresponding 
recyclable activation tags flanking the fragments80. Activation flags contain type 
IIS recognition sequences that allow for cloning in the next round of DNA 
assembly, besides allowing for screening of positive transformants due to the 
encoded antibiotic resistance markers. The use of sequence-specific blocking 
oligonucleotides that prevent DNA methylation at desired restriction sites has 
solved the “forbidden site” issue. A 91 kb completely synthetic right arm of S. 
cerevisiae chromosome IX was constructed using this method80. Programmed 
DNA methylation for preventing digestion by certain RE has been described also 
in the Methylation-assisted Tailorable Ends Rational (MASTER)86 ligation 
method and in the Green Gate system85. The latter still uses BsaI and methylated 
oligonucleotides while MASTER uses MspJI that shares properties from type IIM 
and type IIS RE, recognizing only methylation specific sites and cutting outside 
of its asymmetric recognition sequence, respectively. 
Besides allowing for combinatorial studies, creation of libraries and assembly of 
large constructs, the most important benefit of choosing Golden Gate cloning and 
successors regards assembly of repetitive sequences as exemplified by cloning of 
Transcription Activator Like Effectors (TALEs)145–148. A major problem that has 
not been solved is the fact that type IIS restriction sites occur frequently in 
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mammalian promoters and genes121. Furthermore, the ligase dependency is also a 
limitation. 
5.2. Site-specific recombination-based approaches 
Various nucleotide recombination mechanisms are nature’s way to embrace 
diversity and evolve. Enzymes involved in recombination have also been 
exploited for decades to artificially and rationally recombine DNA molecules, 
both in vivo and in vitro. The typical process of recombination involves one or 
more proteins that recognize and catalyse the shuffling of homologous 
sequences149,150. The homologous sequence stretches are typically in the range of 
30-100 nucleotides and this can represent a methodological limitation (e.g. long 
oligonucleotides are more expensive, might favour secondary structures and 
create difficulties during PCR)151. On the other hand, recombination-based 
methods have high fidelity and efficiency and have proven superior for formation 
of very large constructs such as for whole genome construction58,111.  
Site-specific recombination mediated by phage integrases is conservative and 
highly specific since they recognize versions of attachment (att) sequence motifs, 
attP (P originally for phage – donor DNA) and attB (B for bacteria – receptor) 
DNA sequences found in the phage and host genomes, respectively152. The 
phage-coded integrase and the bacterial integration host factor (IHF) bind tightly 
to the attP site. The complex then couples with attB in the host genome. The 
strand exchange happens after DNA nicks are produced at the ends of the core 
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sequence of both attP and attB sites forming the two-hybrid att sites, attL (left) 
and attR (right). Gateway® cloning88,89 takes advantage of a λ integrase to mediate 
site-specific recombination (Figure 4). 
 
Figure 4 – Overview of the Gateway® cloning system. The gene of interest (goi 
- blue) is cloned into the entry vector flanked by attL sequences. The goi can then 
be transferred to the destination vector, the application-specific vector into which 
the DNA will be sub-cloned. This destination vector carries a ccdB gene (red) 
flanked by attR sequences. Both vectors are mixed, in vitro, with recombination 
proteins. Recombination of attL1 (light orange) with attR1 (yellow) and attL2 
(light green) with attR2 (light blue) creates attB1 (brown) with attP1 (pink) and 
attB2 (grey) with attP2 (purple) sites, respectively. The product of this reaction is 
 29 
the final vector (or expression clone), which carries the DNA of interest flanked 
by attP sites, and the donor vector (crossed with a red line), which contains the 
toxic ccdB gene flanked by attB sites. Selection of final vector after 
transformation is done by using the desired antibiotic (in this example, 
chloramphenicol – cmR in orange) and guaranteeing that cells containing the 
ccdB-encoding plasmid do not survive. 
 
The method requires an entry clone (attL1-goi-attL2), that contains the gene of 
interest intended for cloning, and a destination vector (attR1-ccdB-attR2), in 
which the DNA will be sub-cloned88. The ccdB gene, encoded in the destination 
vector, inhibits E. coli growth153,154, and together with different antibiotic 
resistance markers, allows for a more efficient screening88. This assembly 
strategy relies on several mutated att sites that exhibit high specificity and 
virtually no cross talk. This means attL1 recombines only with attR1 and not 
attR2 and so on. The creation of multiple variants of the attL/attR pair has 
allowed for multisite gateway cloning to stich up to four DNA fragments in a 
single reaction155,156. 
Gateway® cloning is reliable, efficient and widely used in both prokaryotes and 
eukaryotes69,157,158 and a plethora of destination vectors have been constructed by 
the Gateway® research community159,160. Being a commercial available tool 
means that there is a working–for–profit centre responsible for maintenance, 
benchmarking of protocols and dissemination of vectors, which greatly enables 
standardization. 
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The recently published Serine Integrase Recombinational Assembly (SIRA)90 
relies on ϕC31 integrase to assemble pre-designed pathways from DNA parts 
while Site-Specific Recombination-based Tandem Assembly (SSRTA)91 uses an 
alternative integrase, ϕBT1. As Gateway® cloning, these methods depend on 
recombination at att sites that can be reversible by addition of an excisionase (a 
phage protein that allows for excision of DNA sequences) or by a combination of 
integrase and recombination directionality factor (accessory protein that reverses 
the reaction together with the integrase)161. The latter was shown to be extremely 
useful for re-cycling of parts in SIRA90. 
Both Gateway® cloning and SSRTA have a major disadvantage when compared 
to SIRA or other non site-specific recombination methods, which is the need for 
an entry clone that adds an extra cloning step and, hence, more complexity. 
Moreover, recombinase-based cloning leaves long palindromic scar sequences 
that might interfere with DNA integrity or gene expression. However, the high 
efficiency and accuracy of site-specific recombination-based methods make them 
a popular choice for both plasmid construction and genome engineering. A good 
example of site-specific recombination-based genome integration is the recently 
described clonetegration162. Clonetegration vectors were constructed with 
integrase-encoding gene and attP sequence in the same plasmid, which simplified 
the whole process162. The belief in the full potential of combining this technology 
with a simple DNA assembly strategy was the reasoning behind Paper I, in this 
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thesis. Direct genome integration of a six-fragment whole biosynthetic pathway 
in one-tube uracil excision reaction was described by combining uracil excision 
(see next section) with clonetegration. This powerful combination made the 
process more efficient and simple since it prevents the use of restriction-ligation 
or additional less efficient and straightforward methods. 
5.3. Long overlap-based assembly 
Some of the most popular alternatives to the hitherto described methodologies fall 
into the category of long overlap-based assembly. This group includes all the in 
vivo or in vitro DNA assembly strategies that enable the stitching of DNA parts 
with homologous sequences at their ends, allowing for formation of longer 
compatible single-stranded overhangs when compared to the short overhangs 
generated by restriction methods63,68. Homologous recombination has important 
advantages over site-specific recombination since no specific sequences are 
required. There is also the possibility of specific-order assembly in a one-pot 
reaction. These arguments are also the biggest disadvantages of these methods 
since they prevent combinatorial studies, modularity and re-usage of parts for an 
alternative assembly strategy, unless the overlap sequence is general117.  
The Overlap Extension Polymerase Chain Reaction (OE-PCR)92,93 was described 
more than 25 years ago and is one of the first examples of overlap-depend 
cloning. PCR-generated fragments flanked by homologous sequences are mixed 
together in a second round of PCR, where they anneal and enable extension by 
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DNA polymerase92,93,163. The amplicon can then be inserted into a plasmid using 
another cloning strategy92,93,163. The Circular Polymerase Extension Cloning 
(CPEC)94,95 is an improvement to OE-PCR. The homology-sharing parts anneal 
and circularize generating nicked sequences that are then fixed in E. coli after 
transformation. The simplicity of the methods limits their potential for more 
complex DNA assembly projects, mainly due to all the shortcomings that come 
with PCR-based methods such as being error prone (especially when exponential 
amplification of misannealed sequences occurs) difficulty to amplify large DNA 
parts and need for case-by-case optimization. 
Several other methods rely on PCR for part amplification but with the additional 
use of alternative enzymes to create overlapping single-stranded overhangs that 
catalyse efficient and accurate assembly. One example is the so-called uracil 
excision cloning (or uracil-specific excision reagent - USER - cloning)99–103,134,164 
(Figure 5). It is based on the use of uracil-containing oligonucleotides where the 
uracil (U) replaces selected thymines (T) in a non-mutagenic and PCR-tolerated 
alternative base pairing with an adenine nucleotide on the complementary strand. 
This PCR-tolerance is accomplished with non proof-reading enzymes like Taq 
DNA polymerase or special, engineered proof-reading DNA polymerases that 
read through uracils such as PfuX7165 or Phusion-U DNA polymerase (Thermo 
Scientific). Following PCR, uracils can be selectively removed by treatment with 
a uracil DNA glycosidase (UDG) that removes the uracil base and leaves a 
 33 
chemically unstable phosphoribose backbone (abasic site). The lyase activity of 
Endonuclease VIII breaks the phosphodiester backbone at the 3´ and 5´ sides of 
the abasic site guaranteeing that the base-free deoxyribose is released, and 
creating a nick in each of the homology regions. Dissociation of the upstream 
sequence allows the formation of a cohesive DNA end, the U-overhang, and the 
consequent annealing of complementary sequences103. 
 
Figure 5 – Overview of uracil excision cloning. The assembly of PCR 
fragments (insert and vector) is mediated by 3´-TNxA-overhangs (orange and 
green), where X typically denotes 7-12 nucleotides. The uracil in the 5´-ANxU 
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sequence is incorporated in the PCR oligonucleotide used to amplify the parts. 
Uracil is selectively removed by the combined action of uracil DNA glycosylase 
(UDG) and the lyase activity of Endonuclease VIII (USER – represented by a red 
magnet), creating a nick. A 3´-TNxA-overhang is generated when the 
complementary nicked sequence is dissociated, which allows for annealing of 
parts at proper temperature. 
 
Papers I and II, included in this thesis, describe the optimization of this 
technology with increased efficiency and accuracy for both plasmid and genome-
based assemblies in E. coli in a one-pot uracil excision reaction. Apart from E. 
coli, this technology has been also developed for Gram positives like Lactococcus 
lactis166, yeast167,168 and mammalian systems169. Despite its PCR-dependency, the 
most frequently pointed shortcoming of this strategy is the high cost of uracil-
containing oligonucleotides, an argument that is gradually loosing its strength as 
the cost of these oligonucleotides is currently decreasing. Additionally, it has 
recently become possible to order uracil-containing synthetic genes that allow for 
PCR-independent assembly and overcome the PCR disadvantages (Anja 
Martinez, Thermo Fisher Scientific, personal communication). The drawback of 
this method is the requirement of at least one thymine (T) in the assembly 
junctions to be replaced by a uracil (U). This might be an issue specially for 
seamless cloning in high GC content-parts but degeneracy of the genetic code is 
usually a simple solution. 
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Alternatively, a whole different branch of overlap-based assembly strategies aims 
at establishing enzyme-free DNA assembly procedures. One of the most recent 
examples is the phosphorothioate-based ligase-independent gene cloning 
(PLICing)107 that relies on the chemical cleavage reaction of phosphorothioate 
bonds in an iodine/ethanol alkaline solution. Homology-sharing parts are PCR 
amplified with oligonucleotides containing phosphorothioated nucleotides, in 
which phosphodiester bonds are replaced for phosphothioester bonds at the 5’-
end, and then cleaved in an iodine/ethanol alkaline solution to produce the 
cohesive ends107,170. Preventing the need for enzymes might be an advantage but 
the cost of phosphorothiated oligonucleotides is still high and from our 
experience appears to be highly error prone. 
 
“Chew-back and anneal” methods that rely on repair enzymes with exonuclease 
activity, such as T4 DNA polymerase, T5 exonuclease, exonuclease III or lambda 
exonuclease, offer another alternative to the previously described technologies. 
These approaches are based in single-stranded degradation of an exposed end of a 
part creating an overhang that anneals with a complementary sequence from 
another DNA part.  
One of the first reports of a DNA assembly strategy exploiting the exonuclease 
activity was the ligation-independent cloning of PCR products (LIC-PCR)96. The 
procedure relies on the 3’- 5’ exonuclease activity of T4 DNA polymerase in the 
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presence of a predetermined dNTP (e.g. dCTP for vector and dGTP for insert) to 
generate single-stranded overhangs, complementary between the parts to be 
joined. Different 12-nucleotide sequences without guanines (G) and with a G in 
the 13th position are incorporated in the oligonucleotides used to PCR-amplify 
and linearize the vector while complementary sequences with C in the 13th 
position are used for PCR-amplification of the insert. Defined sequence length is 
accomplished by the presence of the specific dNTP that controls exonuclease 
activity of T4 DNA polymerase. Moreover, the 12 nucleotide-overlapping 
sequence shared between the parts eliminates the need for a ligation step96,171. 
Much like uracil excision cloning, this method relies on one nucleotide, which 
can be viewed as a drawback. The sequence and ligation-independent cloning 
(SLIC)97 is, to some extent, a variation of LIC which removes sequence 
constraints by generating longer single-strand overhangs (>20 bp). Overhang 
annealing might be accomplished with or without RecA, relying on the bacterial 
recombination/repair systems to complete the assembly after transformation. 
The most popular methods belonging to this group of DNA assembly strategies 
are Gibson isothermal assembly111–113 and the commercial In-Fusion® cloning108–
110 system from Clontech®. The first relies on the joint activity of three enzymes: 
T5 exonuclease to create a >20 bp overhang that allows for annealing of 
complementary sequences, Phusion DNA polymerase for gap filling, and Taq 
DNA ligase to seal the nicks. The second, despite being proprietary, probably 
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relies on 3’-5’ exonuclease activity of poxvirus DNA polymerase and requires a 
15 bp homology with a slight increase in efficiency with longer sequences108. 
Some of the most impressive DNA assembly constructs were accomplished using 
Gibson Isothermal Assembly111,172 showing that “chew-back and anneal” 
strategies are suited for assembly of large constructs. Roughly, the overhang 
length can be estimated based on the duration and temperature control of the 
DNA treatment with DNA exonucleases96. However, the uncontrolled chew-back 
of DNA exonucleases leads to the formation of ssDNA overlaps with variable 
length, which is probably one of the biggest shortcoming of exonuclease-
dependent strategies97,173. 
In vivo recombination-based methods have also been described and have a cost-
benefit of preventing the need for commercial enzymes, similarly to enzyme-free 
cloning approaches like the already described PLICing. The Seamless Ligation 
Cloning Extract (SLiCE)98 is one example that replaces the repair enzyme 
cocktail for the cellular DNA repair systems by utilizing bacterial cell extracts to 
assemble multiple fragments. The Single-selective-marker Recombination 
Assembly System (SRAS) is another example that explores the endogenous 
homologous recombination systems of E. coli to assemble parts in vivo174. 
However, the most successful examples take advantage of in vivo and native 
homologous recombination of S. cerevisiae and B. subtilis that are able to take up 
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linear DNA fragments with shared end-overlap and assemble them relying 
exclusively on cellular repair systems58,111,175,176. 
From a general perspective, this heterogeneous group of DNA editing tools might 
have some limitations inherent to the manner ssDNA overhangs are formed. Even 
so, the simplicity and freedom of overhang-design as well as their potential to be 
coupled with other strategies, make them extremely attractive and, hence, a 
popular choice amongst researchers. 
5.4. Bridging oligonucleotide-based methods 
In the early 90s, a new amplification method termed Ligase Chain Reaction was 
first reported177. The method relies on the annealing of four oligonucleotides 
complementary to a specific template and their ligation through the action of a 
thermostable ligase. Recently, a new concept arose based on the premise of the 
previous method in which DNA assembly and synthesis of short sequences can 
be accomplished simultaneously178. Shortly after, a very promising approach 
termed Ligase Cycling Reaction (LCR)114 was described for DNA assemblies of 
up to 20 parts (Figure 6). It consists of a series of denaturation-annealing-ligation 
cycles that allow for DNA assembly via bridging oligonucleotides 
complementary to both ends of DNA parts that are joined by a thermostable DNA 
ligase. 
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Figure 6 – Overview of Ligase Cycling Reaction (LCR). Single-stranded 
bridging oligonucleotides, complementary to the ends of the parts to be joined, 
serve as a template to bring the upper strands of denatured 5’-phosphorylated-
parts together. Then, a thermostable ligase stitches the parts that serve as template 
for ligation of the lower strand, in the second and following cycles. 
Denaturation−annealing−ligation cycles allow for assembly of the two parts into 
the final vector. With this protocol, it is possible to assemble many parts into 
complex DNA constructs. 
 
A consistent drawback of these methods lies on the fact that de novo design of 
bridging oligonucleotides might be required when changing parts. The PaperClip 
strategy116 overcame this issue since it relies on double-stranded bridging 
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oligonucleotides, clips, that allow for multipart assembly. Each clip is designed 
by joining two half clips that are nothing but two annealed oligonucleotides with 
a GCC overhang that allows them to be ligated. Modularity is accomplished 
based on the order in which the clips were created and a three bp scar is created. 
Additionally, half clips are re-usable as long as the corresponding part is needed. 
Despite their potential, these methods require the 5’-phosphorylation of parts. 
Either purchasing phosphorylated oligonucleotides or phosphorylating in-house 
oligonucleotides or parts makes the process more expensive and adds some 
complexity to the whole assembly project. 
 
5.5. Mixed approaches 
Struggling to find the best-suited assembly strategy is common among 
researchers since all of the previously described methods have their limitations. 
The increasing complexity in assembly DNA projects gives rise to DNA 
assemblies that are more laborious and error prone. Hence, a recent trend is to 
combine two or more cloning approaches in tandem to overcome these 
limitations. 
Several studies are resorting to linker regions that remain immutable with 
different assembly projects. Recently, Torella et al.122 described a linker-based 
strategy that combines a first cloning round with restriction endonucleases and a 
second round with Gibson isothermal assembly. Alternatively, the Modular 
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Overlap-Directed Assembly with Linkers (MODAL)117 was developed with 
standardized linker sequences to enable modular construction of different 
plasmids in a one-pot reaction that can call upon different long overlap-directed 
DNA assembly strategies like Gibson isothermal assembly, CPEC or S. 
cerevisiae in vivo DNA assembly. The Biopart Assembly Standard for 
Idempotent Cloning (BASIC)119 is an upgrade of the MODAL strategy associated 
with type IIS restriction enzyme-based mechanisms that allows the orthogonal 
linkers to be added to DNA parts without resorting to PCR. This improvement 
also enables the user to choose between multipart assembly and hierarchical 
assembly via methylation of the linkers.  
Taking advantage of linker-based assemblies, an extension to yeast Golden 
Gate142 was made with the Versatile Genetic Assembly System (VEGAS)179 
where linker regions are added by yeast Golden Gate to allow for homologous 
recombination of several modules in yeast. 
Another example of mixed approaches is the Homerun Vector Assembly System 
(HVAS) that combines the multisite Gateway® cloning system with homing 
nucleases120. Despite overcoming the issue of “forbidden sites” imposed by the 
use of most restriction enzymes, this method creates long scars that may pose a 
problem in gene expression. Additionally, the number of commercially available 
homing endonucleases is currently limiting the methodology to four modules. 
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Finally, HVAS still possesses the limitations of Gateway® cloning with regards 
to the added complexity by the need for a sub-cloning step to an entry vector. 
A similar approach was developed by Guye et al121 where the combination of the 
multisite Gateway® system and homing endonucleases with Gibson isothermal 
assembly allowed for modular construction of up to 11 transcriptional units in 
mammalian cells. The biggest advantage when comparing to HVAS is the fact 
that it enables further rounds of assembly. 
Following the linker-based assembly trend, Paper III included in this thesis 
describes the SEVA linker backbone exchange standard, a SEVA-compatible 
strategy that enables backbone swapping with 20 combinations of classical 
enzymatic restriction/ligation, Gibson isothermal assembly, uracil excision 
cloning and nicking enzyme-based methodology. This simplistic one-tube 
protocol for backbone swapping directly from plasmid stock solutions (so-called 
SEVA cloning) is also freely available to the synbio community, promoting 
standardization. 
Despite possible expression effects the addition of linker sequences might have in 
synthetic circuits, these modular strategies will most likely contribute to a more 
consistent part sharing and increasing complexity of combinatorial studies. The 
freedom to choose a favourite assembly technology while still having “back-up” 
technologies turns them into attractive options. Also, what these mixed 
approaches have in common is translated into a crescent scientific awareness that 
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different strategies work best at different stages of complex DNA assembly 
projects. 
6. Software tools for DNA assembly 
The constant appearance of faster and more efficient DNA assembly strategies is 
being mirrored by the rapid development of new software packages (or assembly 
algorithms) that assist with the whole planning process. Nevertheless, our lack of 
knowledge on important biological mechanisms and parameters is the major 
challenge to achieve complete automated and in silico-based approaches for DNA 
assembly experimental design and optimization180. 
Software tools available for synbio design have been reviewed elsewhere26,181. 
The synbio toolkit employs software resources for genome engineering, part 
visualization and circuit design, among others, but in this thesis the focus will be 
exclusively on the recent developments in DNA assembly planning and 
optimization as well as oligonucleotide design. Table 1 lists several DNA 
assembly strategies and the software tools available for each of them. 
Several computational tools are currently available for oligonucleotide design. 
One example is the PHUSER (Primer Help for USER)104,105 and its improved 
version AMUSER (Automated DNA modifications with USER cloning)106 
platforms that become very useful when designing oligonucleotides specifically 
for uracil excision cloning99–103,134,164. Another example is the GeneDesign 3.0182 
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that enables oligonucleotide design and sequence manipulation and is also 
compatible with uracil excision cloning. 
Oligonucleotide design can be time-consuming, laborious and error-prone, 
especially when dealing with large combinatorial projects. Software-assisted 
experimental planning to minimize cloning rounds and human errors, recycle 
parts and reduce costs enables optimization of the whole process. DNA assembly 
strategies that employ fixed sequences on assembly regions facilitate the 
automated protocol design since there is no requirement for junction design or 
optimization. The process becomes more complex when assisting in sequence-
independent DNA assembly procedures79.  
Algorithms were previously reported for automated DNA assembly with 
BioBrick and BglBrick technologies180 to minimize assembly steps and improve 
the recycling of parts. However, the web-based computer-aided design (CAD) 
software J578,79 for DNA assembly design automation was a pioneer in assessing 
the cost-efficiency of DNA assembly by having DNA synthesis and in-house 
available parts as parameters to consider. Additionally, this tool is compatible 
with scarless multipart DNA assembly strategies such as the previously described 
Gibson isothermal assembly111,112, CPEC94,95, SLIC97 and Golden Gate 
cloning76,77. 
Since linker-based DNA assembly technologies are in fashion, more recently, 
R2o DNA designer117,118 was developed to help with the design of linker 
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sequences compatible with MODAL117. A major breakthrough in assembly 
algorithms emerged with Raven (http://www.ravencad.org), the software tool that 
allows for optimized multipart DNA assembly planning and troubleshooting for 
six cloning strategies71. It is the first interactive DNA assembly tool that 
recalculates alternative assembly plans if the first option fails71. Finally, the 
Clotho v2.0183 is a database for managing all the information related to parts.  
Besides the obvious advantage of helping to eliminate human error, particularly 
in high-throughput projects, computational methods can better deal with the 
inherent stochasticity and complexity of biological systems. Some of these 
computational methods have already been used to control robotic liquid handlers 
which have the capacity to carry out relatively accurate pipetting and 
transportation of labware as well as automate multiple complex modular 
assemblies184–186. Software tool development will enable combinatorial DNA 
assembly studies with unprecedented scale. Additionally, the growing synbio 
software toolkit also extends to computer-assisted DNA synthesis and 
sequencing.  
7. DNA synthesis and sequencing 
DNA sequencing and synthesis are out of the scope of this thesis and have been 
extensively reviewed elsewhere65,187–189. However, since DNA writing, editing 
and reading are inherently complementary technologies and, hence, directly 
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intertwined, this section will briefly sum up the current state of play on DNA 
synthesis and sequencing to understand how developments in both fields can 
affect DNA assembly and synbio. 
A plethora of applications like whole-genome sequencing, metagenomics and 
transcriptomics, is now available thanks to Next-Generation Sequencing (NGS) 
that has revolutionized our ability to read DNA at exponentially decreasing 
prices189. Currently, Pacific Biosciences instruments is producing the longest 
reads, up to 14 kb, though with high error rates190–192. Highest accuracy is 
accomplished with the short reads produced by the Illumina/Solexa technology193. 
In spite of new sequencing technologies being in rapid development189, our ability 
to write DNA is still on a less mature level65. Several companies are synthetizing 
DNA at reasonable prices and most of them are using the Polymerase Chain 
Assembly (PCA) strategy to do so65,194,195. PCA employs a thermostable DNA 
polymerase to assemble many oligonucleotides (with overlapping regions of 15-
25 nucleotides) into longer dsDNA fragments195. Larger size synthetic DNA 
fragments however, are stitched from these smaller parts using one of the 
previously described DNA assembly strategies. Nowadays, DNA pieces from 200 
bp to 3,000 bp are being synthetized from five to 50 oligonucleotides65. Until 
now, synthesis of Mycoplasma genitalium genome (582,970 bp) was the largest 
accomplished DNA synthesis111. 
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GeneArt®, Genscript Biotech Corporation, DNA 2.0 and Blue Heron 
Biotechnologies Inc. dominate the gene synthesis market right now, with 
oligonucleotide synthesis technologies like Integrated DNA technologies (IDT) 
also providing the service188. An important upgrade was accomplished by 
GeneArt®, which, besides the Gibson isothermal assembly-compatible synthetic 
genes, is also synthetizing modified parts compatible with uracil excision cloning 
by incorporation of uracils (Anja Martinez, Thermo Fisher Scientific, personal 
communication). 
The major bottleneck in the gene synthesis process is the synthesis of 
oligonucleotides, since it is an error-prone process188. The recently published 
Sniper cloning196 overcomes this issue by coupling synthesis and high throughput 
sequencing, which enables screening of the correct DNA sequences.  
Synbio projects have benefited greatly from the rapid decline of DNA synthesis 
cost197. Particularly for RE-dependent strategies, DNA synthesis offers the 
advantage of removing possible forbidden sites, overcoming the biggest 
shortcoming of these methodologies. As a whole, developments on DNA 
synthesis and sequencing present the opportunity to manipulate and analyse a 
larger set of parts, which in turn reflects on the throughput level of DNA 
assembly projects.  
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8. Applications 
Applications that come with the fast development of all synbio technologies are 
important for pathway optimization for metabolic engineering, design and 
characterization of gene circuits, synthesis of whole genomes and natural product 
discovery. In line with this idea, Paper IV, included in this thesis, shows how 
software approaches can be powerful tools for natural product and enzyme 
discovery, particularly for a group of enzymes with biotechnological interest, the 
cytochromes P450 (CYPs). CYPs are a superfamily of enzymes found in many 
different taxonomic groups. Natural product synthesis in microorganisms, plants 
and fungi, includes several unique chemical reactions, some of which are 
catalyzed by these CYPs198. Despite their ubiquity and diversity in plants, the 
study and engineering of eukaryotic CYPs is facing several challenges. In higher 
organisms, CYPs are membrane associated, representing a major obstacle in 
expressing and purifying this class of enzymes199. Bacterial CYPs, although 
present in lower number as compared to numbers in eukaryotes, are soluble, more 
stable and exhibit higher activity200,201. Thus, they are easier to engineer, 
overexpress, purify and crystallize199. Paper IV, in this thesis, unravels putative 
CYP-encoding genes from the unexplored marine bacterial genomes and 
demonstrates that all the tested CYPs are successfully expressed in E. coli and S. 
cerevisiae. 
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The expanding synbio toolkit has allowed for certain applications such as 
microbial production of biofuels, biomaterials and pharmaceuticals, among 
others202. However, for specific applications like plant engineering, this toolkit is 
still limited70.  A specific example that supports the relevance of CYPs as well as 
the usefulness of the synbio toolkit is the successful synthesis and commercial 
production of semi-synthetic artemisinin203,204. While the whole biosynthetic 
pathway remains unknown, the production of the intermediate artemisinic acid 
followed by chemical conversion to artemisinin enabled its 
commercialization203,205,206. 
Re-designing of biological systems is an important goal of synbio3–5. The 
synthetic yeast genome project and, specifically, the total synthesis of a 
functional designer chromosome (272,871 bp) of S. cerevisiae is probably one of 
the biggest accomplishments of this field67,207. The fact that uracil excision 
cloning was used to assemble the starting smaller DNA fragments demonstrates 
how this technology and its improvements (described in Paper I and II in this 
thesis) can be helpful to the synbio community66,208. 
These examples prove the value of synbio tools, in this case for production of 
pharmaceutical agents and re-designing new biological systems, although several 
others exist. 
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Concluding remarks and future perspectives 
Synbio is a direct bridge between biology and engineering and its success relies 
on its multidisciplinary nature. 
The unpredictability and complexity of biological systems is undoubtedly the 
biggest challenge that synbio has been struggling with. Engineering of even 
simple biological systems is still a frequently laborious process with several trial-
and-error steps. Despite the efforts of the whole synbio community, 
standardization is also a major challenge that remains to be solved. This thesis 
focused on the development and improvement of strategies that could potentially 
contribute to standardization. Paper I describes our efforts in optimizing the uracil 
excision cloning approach, showing that increased efficiency (20-100%) and 
accuracy especially for longer U-overhangs can be obtained. The versatility of 
this method allows for combination with genome engineering strategies like 
clonetegration. With the right set of plasmids, direct genome integration of a 
whole biosynthetic pathway was accomplished at high accuracy in a one-pot 
uracil excision cloning reaction. Paper II adds to this story a detailed set of tips on 
how to plan and troubleshoot uracil excision-based projects. It also provides 
protocols for site-directed mutagenesis, multigene assembly, one-step cloning and 
genome integration with uracil excision, and for standardized linker-dependent 
uracil excision-based DNA editing pipelines. Future work on uracil excision 
cloning would benefit from compatible software tools like J5, to aid with the 
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planning process, troubleshooting and recalculating the assembly strategy in case 
of failure. 
We took the trendy linker strategy to a new level with SEVA linkers for SEVA 
cloning described in Paper III. This strategy allows for direct plasmid backbone 
exchange and is compatible with several popular choices like uracil excision 
cloning, Gibson isothermal assembly, restriction-ligation and nicking enzyme-
based methodology. The flexibility of the strategy and compatibility with the 
popular SEVA resource makes SEVA cloning an excellent choice for automated 
multiple complex modular assemblies. Besides associating it with robotics, future 
work should focus on expanding the entry and donor vector libraries, and adapt 
the strategy for one-pot multigene assembly.  
Finally, Paper IV shows how software tools can make a difference in scientific 
discovery projects. In this manuscript we exploit the potential of marine bacteria 
for discovery of new cytochromes P450 (CYPs). This group of enzymes is 
responsible for challenging chemistry, making it of great biotechnological 
interest. Genome mining of 19 marine bacteria revealed 26 putative CYPs. In this 
paper, it was demonstrated that five of these enzymes can be produced in the two 
favourite model cell factories, E. coli and S. cerevisiae. Identifying specific 
functions to confirm the in silico predictions as well as optimizing CYP 
expression in yeast should be considered as future work. Additionally, 
engineering these enzymes to use a broader range of substrates could facilitate 
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production of relevant compounds. 
 
Overall, the work described in this thesis reflects the steps taken towards the goal 
of making DNA assembly less laborious, more efficient and compatible with 
other synbio tools. Although there are still many challenges to overcome, I 
believe that my contribution to the synbio toolkit will benefit several research 
projects. 
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ABSTRACT: Simple and reliable DNA editing by uracil excision (a.k.a. USER
cloning) has been described by several research groups, but the optimal design of
cohesive DNA ends for multigene assembly remains elusive. Here, we use two
model constructs based on expression of gfp and a four-gene pathway that
produces β-carotene to optimize assembly junctions and the uracil excision
protocol. By combining uracil excision cloning with a genomic integration
technology, we demonstrate that up to six DNA fragments can be assembled in a
one-tube reaction for direct genome integration with high accuracy, greatly
facilitating the advanced engineering of robust cell factories.
KEYWORDS: molecular cloning, DNA assembly, uracil excision cloning, genome engineering
Synthetic biology encompasses the combining of genes frommultiple sources into optimized or novel biosynthetic
pathways. In order to do so, the synthetic biology community
needs to have easy access to genes, genomic parts, and tools for
their assembly.1,2 Owing to the steadily decreasing price of
synthetic DNA, outsourcing DNA editing has become a
popular option.3 However, novel assembly methods or
improved cloning techniques are still frequently reported.2,4−8
This is likely because large genes, whole pathways, and
combinatorial libraries are still relatively expensive to synthesize
and because repetitive or complex sequences are diﬃcult to
produce with standard operating procedures. Thus, synthetic
biology continues to rely on eﬀective methods to assemble
DNA to minimize de novo design and to facilitate exchange of
individual parts at reasonable cost. These methods must be
compatible with a high-throughput format and ideally must be
simple, reliable, ﬂexible, seamless, and cheap.2 The uracil
excision cloning technology (a.k.a. USER cloning) was invented
more than 20 years ago9,10 and increased in popularity with the
development of compatible high-ﬁdelity DNA polymerases, like
PfuTurbo CX Hotstart and PfuX7.11−14 Uracil excision cloning
is a highly versatile, sequence-independent DNA assembly
technology that facilitates simple manipulations such as site-
directed mutagenesis, complex multigene assemblies, and
standardized biobrick assembly pipelines as well as any
combination thereof with simple one-tube protocols.15,16 The
recently developed PHUSER and AMUSER software17,18
further facilitate the in silico design processes.19 The present
study aims to improve the established uracil excision cloning
methodology and to show its potential in combination with
genome engineering.
■ RESULTS
Eﬀect of Using Assembly Junctions with Diﬀerent
Melting Temperatures. In uracil excision cloning, the
assembly of PCR fragments is mediated by 3′-TNxA overhangs,
where x typically denotes 7−12 nucleotides.14,20 A 3′-TNxA
overhang is generated when the complementary 5′-ANxU
sequence that is incorporated in the PCR oligonucleotide is
selectively removed by uracil DNA glycosylase (Figure 1a). To
explore the optimal design parameters of TNxA overhangs, we
ampliﬁed a plasmid encoding constitutively expressed gfp with
oligonucleotides containing ANxU sequences with predicted
Tm’s of circa 10, 20, 30, 50, and 60 °C (Figure 1b,c, using
oligonucleotide nos. 2−11 for creating one PCR fragment and
nos. 2−41 for four fragments; see Supporting Information
Table S1). The template (pET_Duet_GFP_stop, Supporting
Information Table S2) contains an internal stop codon in the
gfp ORF that is removed upon reassembly (Figure 1d).
Counting the number of colonies after transformation allowed
the eﬃciency of assembling one or four fragments to be
assessed, and the accuracy was judged by the green-to-white
colony ratio (deﬁned as the percentage of green colonies). For
both the one- and four-fragment assemblies, junctions with a
Tm of 10−30 °C were assembled with 85−96% accuracy
(Figure 1e,f, white diamonds). With these junctions, the
eﬃciency was 42 000 to 65 000 colonies per microgram of
DNA for one-fragment and 4400 to 19 300 colonies per
microgram of DNA for four fragments (Figure 1e,f, white bars).
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Increasing the Tm of the ANxU sequences to 50 and 60 °C
resulted in fewer correct recombinants for the one-fragment
assembly, and it completely impaired the four-fragment
assembly.
Optimizing the Annealing Step in Uracil Excision
Cloning. Previously described uracil excision DNA assembly
protocols typically include an initial incubation at 37 °C for
enzymatic removal of the uracil base and optimal cleavage of
the phospho-ribose backbone and a second incubation at 25 °C
or room temperature (RT) for assembly of the cohesive
ends.14,15,18,21 However, an assembly junction with a Tm below
RT may not assemble eﬃciently, and in a junction with a Tm
above 37 °C, the nucleotides upstream from the excised uracil
may not be released eﬃciently prior to fragment assembly.
Thus, we hypothesized that the eﬃciency of uracil excision
cloning could be improved by including an incubation step
around the Tm of the most stable assembly junction, followed
by a 10 °C incubation step to ensure eﬃcient assembly prior to
transformation. This change in the protocol signiﬁcantly
increased both the cloning eﬃciency and accuracy for all
ANxU sequences tested, independent of the number of
fragments assembled (Figure 1e,f, black bars). Strikingly,
Figure 1. Illustration of uracil excision cloning, model assembly assay, and optimization. (a) TNxA overhangs are generated by uracil excision when
ANxU sequences are incorporated in the oligonucleotides used in the PCR. (b) Oligonucleotides were designed to vary in the length of ANxU
overhangs corresponding to melting temperatures (Tm) from 10 to 60 °C. (c) The plasmid pET Duet_ GFPstop (gfp ORF with an internal stop
codon is represented in white) was used as a template for PCR ampliﬁcation of one or four DNA fragments with uracil-containing oligonucleotides
(colored arrows correspond to the oligonucleotides illustrated in (b)); (d) uracil-containing fragments were assembled in the uracil excision reaction,
resulting in an intact gfp expressible from the leaky Ptrc promoter; eﬃciency of (e) one- and (f) four-fragment DNA assemblies via uracil excision
cloning in colonies/μg of DNA for chemical transformation of 2.5 μL of the uracil excision mixture into Escherichia coli. Results represent mean
values of at least three independent experiments with standard error. The original protocol is shown in white bars, and the optimized protocol with
puriﬁed and unpuriﬁed DNA parts, in black and gray bars, respectively. Accuracy as a percentage of correct clones is represented as white diamonds
for the original protocol and black or gray diamonds for the optimized protocol with puriﬁed and unpuriﬁed fragments, respectively.
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using this protocol, both one and four fragments can be
assembled with almost 100% accuracy using ANxU sequences
with a Tm < 30 °C. With the 50 and 60 °C overhangs, the four-
fragment assembly was successful only with the newly
optimized protocol at an accuracy of circa 90%.
Assembling DNA Fragments Directly from the PCR.
Uracil excision cloning enables assembly of unpuriﬁed PCR
products because the generated 3′ ends are not ﬁlled in by
excessive DNA polymerase activity (similar to the principle of
Gibson assembly, where a 5′−3′ exonuclease is preferred over a
3′−5′ exonuclease to avoid competition from the activity of
DNA polymerase7) and because the USER enzyme is active in
most PCR buﬀers.11 This feature is attractive, as it is time-
saving and enables automation. As shown in Figure 1f (gray
bars), four fragments can be eﬃciently assembled with
approximately 80% accuracy directly from unpuriﬁed PCR
products; for one fragment, the eﬃciency and accuracy are even
Figure 2. One-step uracil excision cloning for pathway assembly and genomic integration (u-clonetegration). (a) Schematic representation of the
pCDF_Duet_crtEBIYstop plasmid that contains the β-carotene biosynthetic genes from Pantoea ananatis and illustration of the reassembly with one,
two, or four fragments. (b) Representative plate with colonies containing the assembled carotenoid biosynthetic pathway. (c) Accuracy as a
percentage of correct clones for one- (white bars), two- (gray bars), and four-fragment (black bars) assemblies with 15, 30, and 60 °C U-overhangs.
(d) Schematic representation of the assembly of the pOSIP-KO plasmid and fragments of GFP used to assay u-clonetegration. (e) Representative
plate illustrating the eﬃciency of the direct assembly and genomic integration of the construct leading to gfp expression. (f) Optimization by addition
of ligase or heat induction for u-clonetegration. (g) Schematic representation of the pOSIP-KO plasmid and four/six fragments of the genes of the β-
carotene pathway to assay multigene u-clonetegration. (h) Representative plate with colonies containing the assembled β-carotene pathway in the
genome. (i) Comparison of diﬀerent transformation protocols for u-clonetegration of four fragments (gray bars) and six fragments (black bars).
Results are represented as mean values of at least three independent experiments with standard error.
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higher (Figure 1e). Larger overhangs perform poorly,
suggesting that fragment puriﬁcation is a better choice for these.
Accuracy of Uracil Excision Cloning for Assembly of
Complex Metabolic Pathways. Our uracil excision protocol
enables highly eﬃcient assembly of four DNA parts of variable
size (from 540 to 2700 bp) (Figure 1). To test whether the
optimized protocol enables accurate assembly of several intact
genes in a biosynthetic pathway, we designed a strategy based
on de novo parts’ assembly (sizes varying from 1 to 4.6 kb, using
oligonucleotide nos. 42−66 in Supporting Information Table
S1) inside the four genes, crtE, crtB, crtI, and crtY, of the
carotenoid biosynthetic pathway from Pantoea ananatis.22 The
four genes were expressed in an operon from the T7 promoter
(PT7, Figure 2a). Similar to the gfp-based system described
above, we introduced a stop codon on the template plasmid
within the ORF of crtY (pCDF_Duet_crtEBIYstop, Supporting
Information Table S2). CrtY converts lycopene (red color) into
β-carotene (orange color), and this setup therefore facilitates a
simple colorimetric screen that distinguishes among correct β-
carotene-producing clones (orange), misassembled clones
(white), and lycopene-producing clones derived from the
template plasmid (or constructs misassembled in crtY, both
red). To generate a compatible, highly competent cloning strain
that is capable of expressing crtEBIY from PT7, we developed
uracil excision combined with clonetegration23 (see below) to
integrate genes encoding four variants of T7 RNA polymerase
in the genome of the NEB5α strain. The diﬀerent T7 RNA
polymerases were integrated in the same locus (Supporting
Information Figure S1); each variant of T7 polymerase (T7*,
T7*(T3), T7*(N4), and T7*(K1F)) is under the control of a
lac promoter derivative, Ptac, and leads to diﬀerent expression
levels of genes (high to low, respectively) controlled by PT7.
24
The four strains, NEB5αT7*, NEB5αT3, NEB5αN4, and
NEB5αK1F, were transformed with the carotenoid pathway-
encoding plasmid, and phenotype robustness was evaluated by
colony homogeneity (data not shown). The NEB5αK1F strain
produced the most homogeneous colonies and was selected for
further studies. Assembly accuracy was then determined by
counting the percentage of orange colonies (Figure 2b). One-,
two-, and four-fragment assemblies were performed with three
diﬀerent ANxT overhang melting temperatures of circa 15, 30,
and 60 °C (Figure 2c). For both the one- and two-fragment
assemblies, accuracy was more than 70% for all assembly
junctions, but only the 30 °C ANxT overhang resulted in highly
accurate assembly of four fragments (≈80% orange colonies).
Uracil Excision Cloning for Genome Engineering.
Genomic integration of heterologous genes and pathways is
attractive, particularly for the generation of stable production
strains for industrial scale-up. However, until recently,
integration of large complex pathways in the genome of
Escherichia coli and other bacteria was a laborious task.23 The
recently described clonetegration technology elegantly sim-
pliﬁes one-step DNA cloning and direct genomic integration
into several phage integration sites available in common E. coli
strains.23 Motivated by the eﬃciency of the optimized uracil
excision protocol, we wanted to combine the simplistic features
of the two technologies. By amplifying the Ptrc promoter and
gfp in two fragments and combining them with the pOSIP-KO
plasmid as a third PCR fragment (Figure 2d, using
oligonucleotide nos. 67, 68, and 71−73 in Supporting
Information Table S1 and the template plasmid pET_-
Duet_GFPstop in Supporting Information Table S2), the
sequence was successfully assembled with one-pot uracil
excision and subsequently integrated in the genome with the
aid of the integrase encoded on the pOSIP vector with high
eﬃciency and accuracy, as judged from the number of
ﬂuorescent colonies (Figure 2e). Correct genomic integration
in the same genomic location was conﬁrmed by PCR in 12 out
of 12 tested colonies (data not shown). Adding T4 DNA ligase
increased the eﬃciency by nearly 4-fold and resulted in >60 000
colonies per microgram of DNA (Figure 2f). We also tested the
eﬀect of heat induction for enhancing expression of the
integrase by incubating the cells at 42 °C for 15 min after
transformation, but this decreased the eﬃciency by up to 30%.
T4 ligase did not catalyze assembly in the absence of uracil
excision (Figure 2f). Next, we attempted to assess the accuracy
of uracil excision clonetegration (u-clonetegration) by integrat-
ing multiple genes in the E. coli genome in a one-tube reaction
using the crtEBIY model pathway (Figure 2g). The four-gene
pathway was successfully integrated using the optimized uracil
excision protocol with T4 ligase from four and six assembled
fragments, albeit with very low eﬃciency (Figure 2h,i),
suggesting that four or more fragments are more eﬃciently
transferred to the genome by rounds of subassemblies by PCR-
or plasmid-based ampliﬁcations prior to genome integration. In
contrast to previous reports,14 we were able to combine uracil
excision cloning with electroporation, and this increased the
eﬃciency of u-clonetegration (Figure 2i, gray bars).
Uracil excision cloning is one of the most versatile DNA
assembly technologies available and can be used to perform
scarless assemblies, deletions, insertions of up to 100 bp, and
multiple simultaneous site-directed mutageneses.14,18,21 In our
experience, the short end-homology requirement in the uracil
excision technology is an advantage when assembly junctions
are in sequences with high secondary structure propensity, such
as when two genes are assembled with a terminator in between.
Here, we studied the design parameters for uracil excision DNA
assembly and demonstrated that melting temperatures of the
ANxU sequences between 10 and 30 °C enable highly eﬃcient
and accurate assembly of up to four unpuriﬁed PCR fragments
of diﬀerent sizes. When approaching 10 °C, assembly appears
to be more eﬃcient, but less accurate, and thus the chosen
design is a compromise between these two parameters.
Furthermore, we describe a simple one-tube protocol for
assembling up to six DNA fragments for direct genome
integration in E. coli, greatly facilitating the complex engineer-
ing of multiple genes on the genome.
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SUPPLEMENTARY MATERIALS 
METHODS 
Strains, media and plasmids. Escherichia coli strain NEB5α and its derivatives (see results section) 
were used for cloning and propagation of plasmids (Supplementary Table 1). Chemically competent 
cells of NEB5α and derivatives were obtained as described elsewhere.1 Competency of the cells was 
2.6-3.3 × 107 CFU/μg DNA. NEB5αK1F cells were made electro competent using manufacturers 
protocol (New England Biolabs, Ipswich, USA). Bacteria were propagated on Luria-Bertani (LB) 
agar plates or liquid 2xYT media supplemented with spectinomycin (50 μg mL-1) or ampicillin (100 
μg mL-1) when required. Plasmids were isolated using the NucleoSpin® Plasmid QuickPure Kit 
(Macherey-Nagel, Durën, Germany). A plasmid encoding the carotenoid biosynthetic pathway 
(Genbank accession number D90087) from Pantoea ananatis2 was generously provided by Sheila 
Ingemann Jensen. Constitutively expressed gfp was cloned into the pET-Duet-1 plasmid3 (Novagen, 
Darmstadt, Germany), in which the T7 promoter (PT7) was replaced with a leaky Ptrc promoter. A 
stop codon was introduced in the gfp sequence by site-directed mutagenesis. 
 
PCR conditions and DNA quantification. DNA parts were amplified using the proof-reading 
PfuX7 DNA polymerase4 (PfuX7 clone available upon request) in Cloned Pfu DNA polymerase 
Buffer (buffer available from Agilent technologies, Santa Clara, USA). PCR products were obtained 
with 20 cycles in 50 μL reaction mixtures using a C1000 TouchTM Thermal Cycler (BioRad, 
Hercules, USA). PCR products were purified using a PureLink™ Quick Gel Extraction and PCR 
Purification Combo Kit (Life Technologies, Foster City, USA). Buffers for PCR and cloning 
reactions were purchased from Agilent technologies (Santa Clara, USA) and Invitrogen (Paisley, 
UK). PCR products were quantified using a NanoDrop 8000 (Thermo Scientific, Wilmington, 
USA). 
Oligonucleotide design. All oligonucleotides were purchased from Integrated DNA Technologies 
(Coralville, IA, USA) (Supplementary Table 1) and designed with melting temperatures (Tm) of 
circa 60°C (http://www.thermoscientificbio.com/webtools/tmc/). Uracil excision compatible PCR 
products were obtained using oligonucleotides with overhangs designed with Tm varying from 10°C 
to 60°C.  
Assembly with uracil excision cloning. Uracil excision cloning was adapted from the protocol 
described by Geu Flores et al 5. The uracil excision reaction contained 100 ng of each purified PCR 
product, 5x Phusion HF buffer (Invitrogen, Paisley, UK) or T4 DNA ligase buffer (New England 
Biolabs, Ipswich, USA), 1 U of USERTM enzyme mix (New England Biolabs, Ipswich, USA) in a final 
 
volume of 10 μL. The mixture was incubated for 15 min at 37°C, followed by 15 min at 10°C, 15°C, 
20°C, 30°C, 50°C or 60°C and finally 10 min at 10°C, in a C1000 TouchTM Thermal Cycler (BioRad, 
Hercules, USA). Optionally, 2.5 U of T4 DNA ligase was added after the steps described above and 
incubated at room temperature for 15 min. Reaction mixtures were kept on ice prior to 
transformation into chemically competent E. coli NEB5α (for GFP assemblies) and chemical or 
electro competent E. coli NEB5αK1F cells (for carotenoid pathway assembly). For electroporation, 2 
μL of USER mixture was added to 50 μL electro competent cells and transferred to ice-cold 2 mm 
cuvettes. After pulsing by 2.5 kV in an electroporator, 950 μL of SOC was added and cells recovered 
in 37°C for 1 hour. After transformation, plates were incubated at 37°C for 16 hours and when 
relevant for several days at room temperature for color development. All oligonucleotides used in this 
study are summarized in Supplementary Table 1.  
Uracil excision cloning for genome engineering with clonetegration. Clonetegration was 
performed as previously described.6 In short, the pOSIP backbones and genes to be integrated on the 
genome were amplified with the oligonucleotides listed in Supplementary Table 2 and purified DNA 
parts were assembled with uracil excision cloning in T4 ligase buffer as described above. For 
construction of NEB5α strains containing orthogonal T7 polymerase variants, DNA parts were 
obtained by amplification from pOSIP-KL backbone and each plasmid harboring the T7 RNA 
polymerase variants (Supplementary Table 2). Subsequently, the assembled parts were transformed 
into NEB5α and the integrase modules flipped out as described previously.6 For the GFP assembly 
test, the pET_Duet_GFPstop plasmid was used as template for PCR amplification with 20°C ANxU-
overhang-containing oligonucleotides. For assembly and integration of the carotenoid pathway, 
DNA fragments were amplified with oligonucleotides containing 30°C ANxU-overhangs from 
pCDF_Duet_crtEBIYstop.  Reactions were performed in T4 DNA ligase buffer (New England 
Biolabs, Ipswich, USA) (as described above for assembly with uracil excision cloning) and 2 μL were 
transformed into E. coli NEB5αK1F chemically or electro competent cells. After transformation, 
plates were incubated at 30°C for 20 hours and subsequently at room temperature for color 
development.  
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Supplementary Figures 
 
 
Figure 1S. Validating integration of T7* polymerase variants on the genome of E. coli NEB5a. (a) 
Integration of variants of the T7 RNA polymerase, using uracil excision in combination with 
clonetegration 1, was validated with PCR using a P1 oligonucleotide that anneals on the genome and 
a P2 oligonucleotide that anneals in the integrated DNA. (b) PCR was performed on three colonies 
from each T7 variant constructed and analyzed by agarose gel electrophoresis. The expected PCR 
product size (631 bp) was observed in all the tested colonies.    
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Supplementary Tables 
 
 
 Property Reference 
Strains   
MG1655   
E. coli NEB5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
NEB 
NEBRP01 NEB5α with a T7* RNA polymerase 
integrated, KanR  
This study 
NEBRP02 NEB5α with a T7*(T3) RNA polymerase 
integrated, KanR 
This study 
NEBRP03 NEB5α with a T7*(K1F) RNA polymerase 
integrated, KanR 
This study 
NEBRP04 NEB5α with a T7*(N4) RNA polymerase 
integrated, KanR 
This study 
NEBRP05 NEBRP01 without integrase module  This study 
   
Plasmids   
pUC19 Cloning vector, AmpR NEB 
pET_Ptrc-GFP GFPopt expressed from Ptrc promoter in pET-
Duet-1 
This study 
pET_Duet_GFP stop pET_Ptrc-GFP with stop codon in gfp ORF This study 
N249 T7* RNA polymerase, SpcR [7] 
N377:115 T7*(T3) RNA polymerase, SpcR [7] 
N421:115 T7*(K1F) RNA polymerase, SpcR [7] 
W74 T7*(N4) RNA polymerase, SpcR [7] 
pOSIP-KL Clonetegration plasmid with kanamycin 
resistance and lambda integrase, KanR 
[6] 
pOSIP-KO Clonetegration plasmid with kanamycin 
resistance and 186 integrase, KanR 
[6] 
pE-FLP FLP recombinase-expressing plasmid, AmpR [6] 
pSIJ31B P. ananatis crtEBIY in pCDF_Duet, SpcR unpublished 
pCDF_Duet_crtEBIYsto
p 
pSIJ31B with stop codon in crtY This study 
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Number Sequence Strategy 
1 AACAAGGGUCAATCACCTTCAAACTTGACTACAGC 
Uracil excision 
cloning 
2 ACCCTTGUTAATCGTATCGAGTTAAAGGGTAC 
3 ACAAGGGUATCACCTTCAAACTTGACTACAGC 
4 ACCCTTGTUAATCGTATCGAGTTAAAGGG 
5 AACAAGGGUATCACCTTCAAACTTGACTACAGC 
6 ACCCTTGTTAAUCGTATCGAGTTAAAGGGTAC 
7 ATTAACAAGGGUATCACCTTCAAACTTGACTACAGC 
8 ACCCTTGTTAATCGTAUCGAGTTAAAGGGTACTG 
9 ATACGATTAACAAGGGUATCACCTTCAAACTTGACT
ACAGC 
10 ACCCTTGTTAATCGTATCGAGUTAAAGGGTACTGAT
TTTAAAG 
11 ACTCGATACGATTAACAAGGGUATCACCTTCAAACT
TGACTACAGC 
12 ACGGTATCUCAAAAAGGATCTTCACCTAGATC 
13 AGATACCGUATAATCTCATGCCATCGTGC 
14 ACGGTATCTUCAAAAAGGATCTTCACCTAGATC 
15 AAGATACCGUATAATCTCATGCCATCGTGC 
16 ACGGTATCTTAGUCAAAAAGGATCTTCACCTAGATC 
17 ACTAAGATACCGUATAATCTCATGCCATCGTGC 
18 ACGGTATCTTAGTCCAGUCAAAAAGGATCTTCACCT
AGATC 
19 ACTGGACTAAGATACCGUATAATCTCATGCCATCGT
GC 
20 ACGGTATCTTAGTCCAGTGACTGUCAAAAAGGATCT
TCACCTAGATC 
21 ACAGTCACTGGACTAAGATACCGUATAATCTCATGC
CATCGTGC 
22 AGGTACTAAUCAGCAGCAGTCGCTTCAC 
23 ATTAGTACCUCAAAACGTCTGCGACCTG 
24 AGGTACTAATGUCAGCAGCAGTCGCTTCAC 
25 ACATTAGTACCUCAAAACGTCTGCGACCTG 
26 AGGTACTAATGTCTUCAGCAGCAGTCGCTTCAC 
27 AAGACATTAGTACCUCAAAACGTCTGCGACCTG 
28 AGGTACTAATGTCTTACGGUCAGCAGCAGTCGCTT
CAC 
29 ACCGTAAGACATTAGTACCUCAAAACGTCTGCGACC
TG 
30 AGGTACTAATGTCTTACGGTCGATUCAGCAGCAGTC
GCTTCAC 
31 AATCGACCGTAAGACATTAGTACCUCAAAACGTCTG
CGACCTG 
32 AGCATCAGUGATGTCGGCGATATAGGCG 
33 ACTGATGCUACCGATGGGGAAGATCG 
34 AGCATCAGTAUGATGTCGGCGATATAGGCG 
35 ATACTGATGCUACCGATGGGGAAGATCG 
 
36 AGCATCAGTATCUGATGTCGGCGATATAGGCG 
37 AGATACTGATGCUACCGATGGGGAAGATCG 
38 AGCATCAGTATCTGCAAUGATGTCGGCGATATAGGC
G 
39 ATTGCAGATACTGATGCUACCGATGGGGAAGATCG 
40 AGCATCAGTATCTGCAATCCAUGATGTCGGCGATAT
AGGCG 
41 ATGGATTGCAGATACTGATGCUACCGATGGGGAAG
ATCG 
42 ACGCACUATATTGATAATGCGTGATTAGATC 
43 ATGAATGGUAGGGCGTCCGC 
44 ACCATTCAUTCTCATTACGGAGAG 
45 AACGCGUAAGCCGGGGCGA 
46 ACGCGTUTGATCATCTGGAAGGCTTC 
47 ATAAATGGAUGAGGTGGCGAAGG 
48 ATCCATTTAUACGTTGATACACGCGCTG 
49 AGTGCGUGTCTTCAATTAACAATCTGG 
50 ACGCACUATATTGATAATGCGACATTAGATC 
51 AGAATGAATGGUAGGGCGTC 
52 ACCATTCATTCUCATTACGGAGAG 
53 ATCAAACGCGUAAGCCGGGGCGATATC 
54 ACGCGTTTGAUCATCTGGAAGGCTTC 
55 ACGTATAAATGGAUGAGGTGGCGAAG 
56 ATCCATTTATACGUTGATACACGCGCTG 
57 ATATAGTGCGUGTCTTCAATTAACAATCTG 
58 ACGCACTATAUTGATAATGCGACATTAGATC 
59 ATGCTCTCCGTAATGAGAATGAATGGU 
60 ACCATTCATTCTCATTACGGAGAGCAU 
61 AGCCTTCCAGATGATCAAACGCGU 
62 ACGCGTTTGATCATCTGGAAGGCU 
63 AGCGCGTGTATCAACGTATAAATGGAU 
64 ATCCATTTATACGTTGATACACGCGCU 
65 ATCTAATGTCGCATTATCAATATAGTGCGU 
66 ACGCACTATATTGATAATGCGACATTAGAU 
67 AGATGCAUGGCGCCTAACC 
U-clonetegration 
68 AGCCCTCUAGAGGATCCCCGGGTAC 
69 AGAGGGCUGTTCTGGCAAATATTCTGAAATGAGCTG 
70 ATGCATCUCTAACTAACTAACCCTTAGTGACTCCTG  
71 AGAGGGCUATGCGTCCGGCGTAGAGG 
72 ATGCATCUGATTATGCGGCCGTGTACAA 
73 AGAGGGCUGCGACTCCTGCATTAGGAAAT  
 
Supplementary Table 2. Oligonucleotides used in this study 
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Abstract
Despite decreasing prices on synthetic DNA constructs, higher-order assembly of PCR-generated DNA
continues to be an important exercise in molecular and synthetic biology. Simplicity and robustness are
attractive features met by the uracil excision DNA assembly method, which is one of the most inexpensive
technologies available. Here, we describe four different protocols for uracil excision-based DNA editing:
one for simple manipulations such as site-directed mutagenesis, one for plasmid-based multigene assembly
in Escherichia coli, one for one-step assembly and integration of single or multiple genes into the genome,
and a standardized assembly pipeline using benchmarked oligonucleotides for pathway assembly and
multigene expression optimization.
Keywords: BioBricks, DNA editing, Metabolic engineering, Molecular cloning, Synthetic biology,
Uracil excision cloning
1 Introduction
The polymerase chain reaction (PCR) [1] is a simple yet incredibly
powerful technology that revolutionized molecular biology.
Shortly after the advent of PCR, a handful of methods for assembly
of PCR-amplified DNA into larger constructs was developed. PCR
generates double-stranded DNA flanked by sequences that are
defined by the two PCR primers, and several methods exist that
facilitate the formation of cohesive ends for specific higher-order
assemblies (Fig. 1). Simple features can be added when the oligo-
nucleotides are chemically synthesized. As an example, uracil exci-
sion DNA assembly makes use of oligonucleotides where selected
thymines are replaced by uracils. This is a non-mutagenic and PCR-
tolerated replacement, as the uracil is able to form base pairs with
adenine nucleotides on the complementary strand [2–4]. Follow-
ing PCR, the uracils are selectively removed by treatment with
uracil DNA glycosidase, leaving a chemically unstable phosphori-
bose backbone. At elevated temperatures, the upstream sequence
T.J. McGenity et al. (eds.), Hydrocarbon and Lipid Microbiology Protocols, Springer Protocols Handbooks,
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dissociates, generating a single-stranded DNA overhang. A recently
developed similar approach uses phosphorothioate (PTO)-
modified synthetic oligonucleotides [5]. PTO-modified DNA is
converted to single-stranded DNA by treatment with a solution
of iodide and ethanol. Thus, in the case of PTO, the formation of
cohesive ends is enzyme-free. Another enzyme-free route to cohe-
sive ends on PCR products involves the use of two pairs of highly
similar oligonucleotides, but of slightly different length, for ampli-
fication of the same DNA template [6]. When the resulting two
Fig. 1 Illustration of different methods to create cohesive ends on PCR fragments for specific higher-order
assemblies. In the schematic examples, all four methods can generate the same 30 cohesive ends that are not
filled in by excess DNA polymerase activity from the PCR. Thus, all methods can in principle be employed
directly after PCR with no prior purification. S denotes the phosphorothioate modification employed in the PTO/
PLICing cloning technology. I! denotes iodine and etOH denotes ethanol. For more information and refer-
ences, see main text
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PCR products are mixed, denatured, and reannealed, the two
products recombine and form single-stranded ends defined by the
length difference of the two oligonucleotide pairs. However, this
approach complicates the PCR setup (and doubles the price tag)
and does not seem to be extensively used. Finally, exonuclease-
catalyzed recessions of the ends of the DNA are heavily used alter-
natives, e.g., in the form of ligase-independent cloning (LIC) [7] or
the commercially available cloning kit Gibson Assembly [8].
In our experience, uracil excision excels in robustness, simplic-
ity, and price tag. This may be explained by the relatively short
overlap sequence that uracil excision requires (typically 7–12
nucleotides [9], compared to, e.g., 12 nucleotides for PTO-based
cloning [5] and 40 nucleotides for Gibson Assembly [10]). Theo-
retically, DNA fragments with cohesive ends should recombine
with the same efficiency independently of how the single-stranded
ends were generated. However, the protocol, purity, and quality of
the DNA overhangs make all the difference. The quality and yield
of synthetic oligonucleotides is typically low when approaching a
size of 100 nucleobases [11]. Therefore, PCR-based assembly
technologies that use short oligonucleotides are probably less
error prone and more efficient. Moreover, short functional ele-
ments, such as promoters or ribosome binding sites, can easily be
correctly incorporated directly in oligonucleotides that are assem-
bled using short overlap sequences, because the total length of the
oligonucleotide is kept relatively short. In our experience, 50 “tails”
(sequence added at the 50 end of the oligonucleotides that do not
anneal to the template DNA in the first PCR cycles) up to more
than 100 nucleotides are possible, but often negatively affect the
PCR yield.
Another way to ensure oligonucleotide quality is to build a
molecular cloning pipeline that reuses benchmarked oligonucleo-
tides. This was recently demonstrated for the uracil excision assem-
bly and engineering of a six-gene biosynthetic pathway for
porphyrin production [12] and a seven-gene heterologous pathway
for production of a diterpene in Escherichia coli [13]. This type of
standardization perfectly fits large collaborative efforts, much like
BioBricks in the global iGEM project [14], and reuse of parts also
enables better comparison of data.
Protocols for simple and seamless assembly of PCR products
(also known as USER fusion), and the corresponding primer
design, have been described and reviewed previously [15, 16].
Here, we provide protocols for simple manipulations and more
complex assembly pipelines, including site-directed mutagenesis,
multigene assembly, one-step cloning, and genome integration
with uracil excision, and for a standardized, BioBrick uracil
excision-based DNA editing pipeline.
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2 Materials
2.1 Strains, Media,
and Antibiotic
Selection
1. Bacterial strains: E. coli strain NEB5α (New England Biolabs,
Ipswich, USA) is used as a cloning host. E. coli BL21, K12
MG1655, and KRX (Promega, Madison, USA) are used for
uracil excision combined with genomic integration (see
below).
2. Growth media: SOC (20 g Bacto-Tryptone, 5 g yeast extract,
10 mM NaCl, 2.5 mM KCl, 20 mM MgSO4, 20 mM glucose,
water up to 1 L), 2!YT (16 g Bacto-Tryptone, 10 g yeast
extract, 5 g NaCl, water up to 1 L), and LB (10 g Bacto-
Tryptone, 5 g yeast extract, 10 g NaCl, water up to 1 L) (all rea-
gents can be purchased from Sigma-Aldrich, St. Louis, USA).
3. Antibiotics: chloramphenicol (25 μg/mL), kanamycin
(50 μg/mL), and tetracycline (50 μg/mL) (Sigma-Aldrich,
St. Louis, USA). For clonetegration, half concentration is
used with all antibiotics.
2.2 PCR Components 1. DNA polymerase: uracil excision-compatible PCR products are
amplified using the proofreading PfuX7 DNA polymerase [17]
(see Note 1). Cloned Pfu DNA Polymerase Buffer (Agilent
Technologies, Santa Clara, USA) is used to buffer the reaction
mixture.
2. Oligonucleotides (Integrated DNA Technologies, Inc., Coral-
ville, USA) are designed with melting temperatures (Tm) of ca.
60"C. Additionally, all oligonucleotides contain one uracil, typi-
cally placed 7–12 nucleotides from the 50 end (see Note 2).
Upon uracil excision, the generated single-stranded ends
should have melting temperatures between 10 and 30"C [18]
(see Note 3).
3. Template DNA: plasmid DNA is isolated using theNucleoSpin®
Plasmid QuickPure Kit (Macherey-Nagel, Bethlehem, USA).
Plasmid aliquots are kept at #20"C (see Note 4).
4. PCR purification: PCR products are purified using a PureLink™
Quick Gel Extraction and PCR Purification Combo Kit
(Thermo Fisher Scientific Inc., Waltham, USA).
5. Template DNA removal:DpnI (20,000 U/mL) (New England
Biolabs, Ipswich, USA) is used to degrade methylated template
DNA after the PCR.
2.3 USER Cloning 1. USER™ enzyme mix (New England Biolabs, Ipswich, USA).
2. USER reaction is performed in 5! Phusion HF Buffer (Life
Technologies, Grand Island, USA) or Cloned Pfu DNA Poly-
merase Buffer (Agilent Technologies, Santa Clara, USA).
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2.4 Plasmid DNA 1. Vectors: a series of pOSIP vectors is described in St-Pierre
et al. [19] and can be obtained from Addgene (Addgene,
Cambridge, USA). Duet vectors are available from Merck
Millipore (EMD Millipore, Billerica, USA) or Addgene.
3 Methods
The protocols described here showcase the versatility of the uracil
excision methodology and include protocols for (1) simple introduc-
tions of mutations, deletions, and insertions in DNA, (2) multigene
assembly, (3) direct assembly and genome integration, and (4) using
standardized BioBricks for assembly of pathways. The first uracil
excision protocol describes the introduction of mutations, inser-
tions, or deletions by one-fragment whole-plasmid synthesis and is
largely based on the overall principles described by Nørholm [17].
Multigene assembly is performed as described previously [20] with
some modifications. The third uracil excision protocol adds direct
genome integration (clonetegration [19]) to the uracil excision
portfolio. The optimal design parameters for multigene assembly
and uracil excision combined with clonetegration have recently
been explored [18]. Detailed information on clonetegration includ-
ing vectors and an oligonucleotide list for colony PCR is described in
St-Pierre et al. [19]. The fourth uracil excision protocol describes two
operations of a fully standardized assembly procedure. The first stan-
dardized operation encompasses cloning of genes of interest into an
entry vector using gene-specific oligonucleotides with fixed exten-
sions mediating cloning. This vector contains all elements required
for protein production in E. coli and can therefore be used straight-
away for monitoring proper transcription and translation. The second
standardized operation is assembly of entry fragments into multigene
constructs using pairs of oligonucleotides with generic annealing
parts, but distinct cloning mediating extensions. These oligonucleo-
tides facilitate directional and specific assembly of any number of
fragments. For detailed description of the options and limitations of
such a standardized design, please refer to Nielsen et al. [12].
3.1 PCRs The PCRs are performed using 1 μL PfuX7 DNA polymerase (the
optimal concentration is typically batch dependent and should be
empirically determined when purifying the polymerase – after
desalting of his-tagged-purified PfuX7 [17], we typically determine
the optimal concentration by titrating the amount of PfuX7 in a
standard PCR reaction), 5 μL 10! Cloned Pfu Polymerase Buffer,
5 μL dNTP mix (25 mM each of dATP, dTTP, dGTP, dCTP), 2 μL
DNA template (150 ng μL), 5 μL forward primer (5 μM), 5 μL
reverse primer (5 μM), 1.2 μLMgCl2 (50 mM) (it may be advanta-
geous to optimize the MgCl2 concentration from batch to batch
PfuX7 by titrating the final concentration from 1 to 5 mM), and
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29.8 μL nuclease-free water. The PCR involves an initial denatur-
ation step at 98!C for 2 min, then 20 cycles of 98!C for 20 s, 58!C
for 20 s, and 72!C for 45 s/kbp. Finally, the thermocycler is
programmed for 72!C for 8 min and stored at 12!C.
3.2 Analysis and
Purification of PCR
Results
PCR products are analyzed by standard agarose gel electrophoresis.
The resulting PCR products may be purified using any PCR
cleanup kit.
3.3 Simple Protocol
for Site-Directed
Mutagenesis,
Insertions, or
Deletions
Mutations, deletions, or insertions in plasmid constructs are made
by amplifying the whole plasmid with uracil-containing oligonu-
cleotides that incorporate these new features. The extraordinarily
simple protocol involves adding USER™ enzyme mix and DpnI
directly to the PCR reaction mix described above; incubate for 1 h
at 37!C and 20 min at 16!C in a thermocycler followed by direct
transformation of 3 μL of the reaction mixture into 17 μL chemi-
cally competent cells (see Sect. 3.5). Oligonucleotide design is very
flexible, but general guidelines can be found in Sect. 2.2, and it is
recommended to try software-assisted design tools such as
AMUSER [21].
3.4 Uracil Excision-
Assisted Multigene
Assembly
3.4.1 Simple Multigene
Assembly with Non-
purified Fragments
For assembly of two or more fragments, equal volumes of each
PCR reaction are mixed in a total volume of 10 μL and buffered
using the 5" Phusion HF Buffer (see Note 5). For template
removal, DpnI is added prior to USER™ enzyme mix and incu-
bated for 1 h at 37!C. The DpnI enzyme is deactivated by incuba-
tion at 65!C for 10 min. After 5 min on ice, 1 μL of USER™
enzyme mix is added to the reaction tubes, and uracil excision is
accomplished by incubating the sample at 37!C for 15 min. Subse-
quently, DNA assembly is executed by cooling down the reaction to
below the melting temperature of the cohesive ends for at least
15 min.
3.4.2 Multigene
Assembly with Purified
Fragments
PurifiedDNA fragments (seeNote 6) are assembled as described for
the non-purified DNA fragments except that 100 ng of each frag-
ment is used and theDpnI-assisted template elimination step can be
omitted.
3.5 Chemical
Transformation of
E. coli NEB5α Cells
17 μL of chemically competent E. coli NEB5α cells are mixed with
3 μL of the assembly mix described above and incubated for 15 min
on ice followed by a heat shock at 42!C for 1 min (see Note 7).
Following the heat shock, 1 mL of LB medium is added, and the
cells are incubated for 1 h at 37!C, followed by plating on solid LB
medium with the appropriate antibiotic selection for 16 h at 37!C.
For selection with antibiotics like ampicillin or carbenicillin, the
cells can be spread without a 1 h recovery step.
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3.6 One-Step Uracil
Excision Assembly and
Genome Integration
Amplify one of the pOSIP backbones (see Note 8 and [19]) with
the oligonucleotides 50-AGATGCAUGGCGCCTAACC-30 and
50-AGCCCTCUAGAGGATCCCCGGGTAC-30 and the DNA to
be integrated on the genome with 50-AGAGGGCU-30 followed by
a gene-specific forward annealing sequence and 50-ATGCATCU-30
followed by a gene-specific reverse annealing sequence using the
PCR conditions described above. Gel purify the amplified DNA,
and make an assembly mix as described above except for using a
molar ratio of 3:1 between insert and vector. Transform E. coli cells
as described above. Recover the cells in SOC medium at 37!C for
1 h, spread the cells on LB agar plate containing the appropriate
antibiotic, and incubate the plate at 30!C for 20 h. Perform a
standard colony PCR to confirm the clones are integrated as
described in St-Pierre et al. [19].
3.7 Standardized
BioBrick
Bioengineering
Pipeline with Uracil
Excision
Make initial entry clones by PCR amplifying the pET-Duet-1
vector using the oligonucleotides 50-AGCACTGGUCATTGCTA
ATGCTTAAGTCGAACAG-30 and 50-ACCACTGGUCATTGC
TTATCTCCTTCTTAAAGT-30 (see Note 9). PCR amplify gene-
coding sequences with 50-ACCAGTGGU-30 followed by a gene-
specific forward annealing sequence and 50-ACCAGTGCU-30
followed by a gene-specific reverse annealing sequence. In the
standardized entry clones, 50-ATGACCAGTGGT-30 that translates
into MTSG is added to the 50 end, and 50-AGCACTGGTCA
TTGC-30 that translates into TSGHC is added to the open reading
frame. Make sure that the oligonucleotides anneal in frame with the
coding sequence. At this stage, genes of interest can be tested for
proper transcription and translation using selective 35S-methionine
labeling of gene products in the presence of rifampicin (seeNote 10
and [22]). The standardized 50 end may facilitate a more predict-
able translational initiation rate, as previously described for similar
translational fusions [23, 24], and the standardized 50 and 30
sequences serve as anneal sites for collections of standardized oli-
gonucleotides for higher-order assemblies, independent of the spe-
cific genes inserted in the entry vectors. Higher-order assemblies are
generated with oligonucleotides with the same overall design: linker +
control element + annealing sequence. When generating the pET-
Duet-1-based entry vector as described above, the forward annealing
sequence for downstream multigene assembly is 50-ATAAGCAAT
GACCAGTGGT-30, and the reverse annealing sequence is 50-
TAATGTAAGTTAGCTCACTCATTAG-30. The principle is sche-
matically illustrated in Fig. 2. The setup will allow the buildup of a
library of benchmarked oligonucleotides where differently designed
linkers have been validated for correct assembly. Examples of validated
linkers are 50-ACACCGACU-30/50-AGTCGGTGU-30, 50-
ACGCTGCTU-30/50-AAGCAGCGU-30, 50-AGACGTCAU-30/50-
ATGACGTCU-30, 50-AGGTCTGAGU-30/50-ACTCAGACCU-30,
50-ATAGGCTTU-30/50-AAAGCCTAU-30, and 50-AACGTGGAU-
30/50-ATCCACGTU-30 [12, 13]. Examples of control elements are
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constitutive promoters such as Ptrc followed by randomized Shine-
Dalgarno sequences (for details, see 12] and the phage promoter PT7
followedby the lacoperator andaconsensus Shine-Dalgarno sequence
(for details, see 13]. The protocols for assembly are as described above
(seeNote 11).
4 Notes
1. Commercially available proofreading DNA polymerases with
similar characteristics are available as Phusion U Hot Start
DNA Polymerase (Thermo Fischer Scientific, Pittsburgh,
USA) and KAPA HiFi Uracil+ (Kapa Biosystems, Inc., Wil-
mington, USA).
Fig. 2 Illustration of the two-step, uracil excision-based, standardized pipeline for multigene engineering. (a)
In the first step, genes of interest are cloned with standardized linkers into an entry vector. In the entry vector,
an orthogonal T7 phage promoter allows for assessment of proper transcription and translation by 35S-
methionine labeling in the presence of rifampicin (rifampicin blocks transcription of endogenous genes by
inhibiting the endogenous E. coli RNA polymerase). (b) The standardized linkers allow the use of standardized
oligonucleotides for re-amplification and construction of multigene constructs with benchmarked linkers and
functional elements such as promoters and ribosome binding sites. Linkers for uracil excision are relatively
short, thus allowing for larger control elements to be incorporated in standard oligonucleotides
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2. Oligonucleotides can be designed using the PHUSER or
AMUSER software [21, 25].
3. The melting temperature of the overhangs can be calculated by
online software tools such as the Tm calculator from Thermo
Fischer Scientific.
4. Plasmid aliquots should contain a small volume (max. 50 μL) to
avoid repeated cycles of freeze thawing.
5. According to the supplier (New England Biolabs, Ipswich,
USA), the USER™ enzyme is active in all standard reaction
buffers. We routinely use buffers such as Phusion HF, NEB4,
cloned Pfu buffer, and T4 ligase buffer.
6. In our experience, purification in some cases enhances the
efficiency and fidelity of the assembly reaction, possibly due
the removal of interfering oligonucleotides [18], but it also
complicates the protocol.
7. We routinely use between 30 s and 2 min for heat shock – the
optimal incubation time depends on the plasticware and the
heat block and can be optimized empirically.
8. Clonetegration is highly dependent on the kind of integrase in
the pOSIP vector and the efficiency of the competent cells.
Before you select the strain and vector for integration, check
if the strain contains the attB site in the genome corresponding
to the integrase and attP site in the vector. For example, in the
case of pOSIP-KO (containing phage 186 integrase), MG1655
contains two corresponding attB sites, whereas BL21 (DE3)
contains only one.
9. The protocol is described for uracil excision cloning, since this
is the technique most often applied in our lab. The concept and
principles of standardized assembly, however, are by no means
limited to this cloning technique. On the contrary, the princi-
ples can be implemented with any PCR-based cloning tech-
nique as well as several restriction enzyme-based techniques as
described in Nielsen et al. [12].
10. While his technique should be applicable to all E. coli strains
containing T7-RNA polymerase, it is our experience that BL-21
(DE3) is superior regarding the 35-S labeling of proteins. We
cannot say whether this is attributed to increased uptake and
incorporation of labeled methionine, efficiency of cell lysis, or
another parameter, but in side-by-side comparisons, BL-21
(DE3) consistently gives us the strongest labeling signals. Any
defined media can be used, but we have found that the PASM-
51 media developed by Studier (2005) yields robust expression
of many different protein types in various E. coli expression
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strains. By depleting the media of methionine, more efficient
labeling is achieved.
11. The described oligonucleotides facilitate directional and spe-
cific assembly of any number of fragments, although efficiency
decreases as the number of fragments increases. In our lab, 3–5
fragments (including the vector backbone) are routinely assem-
bled using this protocol.
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ABSTRACT: DNA vectors serve to maintain and select
recombinant DNA in cell factories, and as design complexity
increases, there is a greater need for well-characterized parts
and methods for their assembly. Standards in synthetic biology
are top priority, but standardizing molecular cloning contrasts
ﬂexibility, and diﬀerent researchers prefer and master diﬀerent
molecular technologies. Here, we describe a new, highly
versatile and automatable standard “SEVA linkers” for vector
exchange. SEVA linkers enable backbone swapping with 20
combinations of classical enzymatic restriction/ligation,
Gibson isothermal assembly, uracil excision cloning, and a
nicking enzyme-based methodology we term SEVA cloning.
SEVA cloning is a simplistic one-tube protocol for backbone swapping directly from plasmid stock solutions. We demonstrate the
diﬀerent performance of 30 plasmid backbones for small molecule and protein production and obtain more than 10-fold
improvement from a four-gene biosynthetic pathway and 430-fold improvement with a diﬃcult-to-express membrane protein.
The standardized linkers and protocols add to the Standard European Vectors Architecture (SEVA) resource and are freely
available to the synthetic biology community.
KEYWORDS: synthetic biology standards, plasmid backbone exchange, standard parts characterization, cell factory design
The early steps in engineering of microbial cell factoriestypically involve a choice of vector for gene expression.
This vector enables maintenance (replication) of the genetic
elements of interest, e.g., by containing an origin of replication
or elements ensuring transfer to the microbial genome, and
often includes a selectable trait, in bacteria typically in the form
of antibiotic resistance. These initial choices can have a major
impact on the performance of the cell factory, and balancing
these factors is imperative to optimize production.1,2
Plasmids are extrachromosomal DNA elements that are
nonessential, can replicate autonomously and are easily
modiﬁed in vitro and thus represent an extremely powerful
toolbox for molecular biology. The number of plasmid
molecules in a single cell speciﬁes the amount of gene copies
available for expression, and this copy number is determined by
diﬀerent genetic elements at the origin of replication.3 Toxicity
of plasmid-encoded proteins is usually the highest metabolic
burden for a production host,4 and gene overexpression is a
stress for the organism that needs to cope with this metabolic
overload and prevent the system’s breakdown.2 Moreover, extra
DNA elements and gene expression will likely compete with
the native DNA for essential resources, e.g., the native RNA
polymerase.5,6
In a typical laboratory setup, horizontal gene transfer events
are selected for with the aid of antibiotic resistance genes.
Antibiotics either inhibit bacterial cell growth (bacteriostatics)
or cause bacterial cell death (bactericidals).7 Thus, antibiotic
selection is inherently linked to metabolic burden, ﬁtness costs
and physiological changes.8−11
Most synthetic biology and metabolic engineering projects
require a ﬁrst step of DNA assembly,12−14 and with increasingly
advanced design requirements, simple methods for genetic
elements exchange are highly attractive. Struggling to ﬁnd the
best-suited assembly and exchange strategies is common among
researchers since all of the described DNA cloning methods
possess diﬀerent limitations. Moreover, a consensus method-
ology is hard to agree on: best exempliﬁed with the paradoxical
high number of assembly strategies available at the Registry of
Standard Biological Parts.15 Nevertheless, standardized genetic
parts and methods for their assembly are very important for
continuous progress in the synthetic biology ﬁeld.16,17 For
example, standards surely will enable more systematic and
reliable approaches to assay the performance and robustness of
genetic elements.
Here we attempt to address the standardization paradox by
designing small multifunctional DNA fragments designed to
link together genetic elements often used in bacterial cell
factories. The resulting linkers contain elements enabling
continuous reassembly with several of the most common
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DNA assembly methodologies (e.g., restriction enzymes,
Gibson assembly and uracil excision cloning) and with a new
extraordinary simple protocol for plasmid backbone exchange.
Finally, we demonstrate the usefulness of this resource by
systematically comparing bacterial production of the membrane
protein NarK and the food coloring pigment β-carotene
produced from a four-gene biosynthetic pathway, each with a
total of 30 combinations of origins of replication and antibiotic
resistance markers.
In the Standard European Vector Architecture (SEVA),18,19
diﬀerent rare restriction sites ﬂank three basic genetic elements:
(1) antibiotic selection markers, (2) origins of replication and
(3) the so-called cargo that contains the genetic elements
necessary for the end-application of the cell factory (very often
a promoter driving expression of a gene, Figure S1).
Importantly, these genetic elements have well-deﬁned borders
that are useful for parts exchange and a catalogue of all 54
combinations of nine origins of replication with six antibiotic
resistance markers is available.
Figure 1. Illustration and optimization of SEVA-linker-based backbone exchange. (a) The cargo, here illustrated with a plasmid-encoded gfp, is
ﬂanked by two multifunctional linker sequences altogether hosting a total of nine rare restriction sites and four Nt.BbvcI nicking enzyme recognition
sites (see expanded view). When mixed with the Nt.BbvcI enzyme and a backbone acceptor plasmid, hosting the toxic ccdB gene ﬂanked with the
same linkers, the recombined cargo can be selected on the antibiotic deﬁned by the acceptor backbone. The expanded view of the reaction shows all
assembly possibilities. (b) Left panel: eﬃciency of recombination with diﬀerent ratios of backbone acceptor and cargo donor plasmids, and with the
addition of T4 DNA ligase to the mixture. Right panel: representative picture showing the eﬃcient recombination of a gfp-expressing cargo into a
new backbone acceptor plasmid.
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To make this great resource compatible with a range of state-
of-the-art DNA assembly methods, we designed two multi-
functional SEVA linker sequences that hosted ﬁve and four
additional rare restriction sites, respectively (PacI, NotI, AscI,
SgrDI, MauBI on one side and FseI, Sbf II, MreI, SpeI on the
other side, Figure 1a). This enables backbone swapping with a
total of 20 combinations of these enzymes. Additionally, all
cargo elements, ﬂanked with these linkers, are easily inserted in
Figure 2. Production of β-carotene and the membrane protein NarK with 30 diﬀerent combinations of origins of replication and antibiotic resistance
markers. (a) Upper panel: illustration of the cargo with T7 promoter driven expression of the four-gene crtEBIY biosynthetic pathway. Lower left
panel: colony phenotypes of the crtEBIY cargo combined with ampicillin (Ap), kanamycin (Km), chloramphenicol (Cm), spectinomycin/
streptomycin (Sm/Sp), tetracycline (Tc) or gentamycin selection; and the pBBR1, p15A, pSC101 or pBR322/ROP origins of replication. All 30
combinations were transformed into both E. coli NEB5α::T7* (left side) and NEB5α::K1F (right side) hosting two diﬀerent variants of the T7 RNA
polymerase. No combinations with the high copy pUC origin of replication yielded surviving colonies. Lower right panel: heat map representation of
carotenoid levels measured by acetone extraction and absorbance at 453 nm on the 24 viable backbones variants in NEB5α::T7* and NEB5α::K1F.
(b) Left panel: illustration of the NarK-GFP protein (based on the pdb ﬁles: 1EMA and 4U4V) and cargo constructs. Middle panel: Fluorescence
from E. coli BL21 (DE3) transformed with 30 diﬀerent backbones in combination with the T7-narK-gfp cargo. Right panel: heat map representation
of ﬂuorescence levels quantiﬁed in a microplate reader after four and 24 h expression.
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the existing SEVA system using the outermost PacI and SpeI
sites (but violates the SEVA design rules by reusing the FseI and
AscI sites, Figure S1). The saturation with rare restriction sites
means that it should always be possible to ﬁnd a suitable pair of
restriction enzymes for backbone swapping. In other words this
minimizes the consequence of “forbidden sites” in the cargo.
Moreover, these unique linkers sequences make it possible to
design highly speciﬁc oligonucleotides (for examples see
Supporting Information Table S1) that anneal in these regions,
while hosting features compatible with state-of-the-art DNA
assembly methods such as Gibson isothermal assembly20 and
uracil excision21 (Supporting Information Table S1, Figure S2).
Such oligonucleotides can be performance benchmarked and
kept in the freezer for continuous reuse when assembling new
parts with these technologies.
Another recently popularized assembly method is Golden
Gate cloning.22 One of the biggest advantages of Golden Gate
cloning is that DNA can be exchanged directly from
(compatible) plasmid stock solutions with a simple protocol,
whereas a drawback is the frequent occurrence of the type IIS
restriction sites typically used: “forbidden sites”. Inspired by
some of the features in Golden Gate cloning, we designed an
extension to the SEVA linkers enabling backbone exchange
with a very simple protocol directly from plasmid stocks.
Instead of type IIS restriction sites, our design uses two pairs of
nicking restriction sites (Figure 1a) that together form two
diﬀerent 7 bp cohesive ends (Figure 1a and Supporting
Information Figure S3). We initially used the Nb.BtsI nicking
enzyme, but changed to Nt.BbvCI because the recognition site
is 7 bp and only occurs rarely in standard sized DNA
constructs. Furthermore, because the mutant enzyme only cuts
one strand, occurrences outside the SEVA linker will probably
not aﬀect cloning eﬃciency signiﬁcantly. This solves the
forbidden site issue.
We designed two SEVA-linker-ﬂanked cargo elements, one
expressing lacZ and one expressing gfp, with diﬀerent antibiotic
selection markers, and checked their ability to recombine by
mixing the plasmids together with the nicking enzyme and
plating on media with the diﬀerent antibiotics (Supporting
Information Figure S4). Ultimately, the idea is that a cargo
“donor” plasmid should be transferred to a backbone “acceptor”
plasmid at high eﬃciency and speciﬁcity. To this end, we
incorporated the toxic ccdB gene23 in the backbone acceptor
and selected recombinants by transforming constructs into
standard (i.e., ccdB-incompatible) cloning strains with the
backbone-deﬁned antibiotic selection (Figure 1a). As an initial
proof of concept, we examined gfp ﬂanked by the two SEVA
linkers in the commercially available pCDF backbone
(CloDF13 origin and spectinomycin resistance) transferred to
an acceptor plasmid containing ccdB in the pACYC backbone
(p15A origin and chloramphenicol resistance). We then
observed ﬂuorescent colonies forming on chloramphenicol-
containing plates with high eﬃciency (Figure 1b). Optimization
of the ratio of donor and acceptor plasmids in the reaction
increased eﬃciency approximately 2-fold, whereas adding T4
DNA ligase to the mixture enhanced eﬃciency more than 10-
fold (Figure 1b). The optimized and simple protocol is
described in detail in the Supporting Information. Notably,
rather than getting it right the ﬁrst time, several similar nicking
enzyme-based designs were tested for eﬃciency and speciﬁcity
before we settled on the sequence presented here (see
Supporting Information Figure S5).
We based our further work on the comprehensive pSEVA
collection as a backbone acceptor series. By combining ﬁve
origins of replication (pBBR1: #3, p15A: #6, pSC101: #7, pUC:
#8, pBR322/ROP: #9) and six antibiotic resistance markers
(ampicillin: #1, kanamycin: #2, chloramphenicol: #3, spectino-
mycin: #4, tetracycline: #5, gentamycin: #6), we created 30
diﬀerent backbone acceptors with the counter-selection marker
ccdB ﬂanked by SEVA linkers as the initial cargo.
To assay the performance of our 30 standardized plasmid
backbones in two typical, cell factory-type experimental
settings, we swapped-in the four-gene crtEBIY biosynthetic
pathway for β-carotene from Pantoea ananatis and the
membrane protein-encoding narK-gfp in all 30 constructs.
crtEBIY is industrially relevant and a convenient model pathway
mainly due to the simple product output (orange color), but
also because the robustness of the phenotype seems sensitive to
the cell factory design parameters.24 Indeed, we were unable to
obtain surviving colonies by swapping the pathway into vectors
with the high-copy pUC origin of replication and we obtained
highly variable phenotypes when T7 polymerase was used to
drive expression from the construct in comparison with the
weaker K1F variant (Figure 2a).24−26 Overall, we observed a
10-fold diﬀerence in the β-carotene product titers, from the
lowest to the highest performing cell factories (Supporting
Information Table S3) and several of the combinations showed
clear toxicity and population bias eﬀects (e.g., pBR322/ROP in
combination with chloramphenicol or pSC101 in combination
with tetracycline, Figure 2a). In contrast, the pBR322/ROP
origin in combination with both ampicillin and tetracycline was
highly performing in both expression strains. With the
membrane protein NarK,27 the variation in expression yield
was even more prominent (Figure 2b); the diﬀerence between
the highest and the lowest performing combination of parts was
in this case an impressive 430-fold (Supporting Information
Table S3). Generally, using tetracycline selection, gentamycin
selection or the high copy pUC origin had a negative impact on
narK expression, whereas the p15A origin (low copy number)
and spectinomycin selection seemed to positively impact the
expression level.
Comparing the two diﬀerent test cases, small molecule and
protein production, showcases the value of a synthetic biology
approach (i.e., systematic studies with standardized parts) and
provides future design guidelines and a toolbox for similar
experiments. For example, the high copy pUC origin of
replication is likely a poor choice for anything but DNA
production. The negative impact of the tetracycline selection
may in contrast only reﬂect the fact that the resistance gene
encodes a membrane protein that could compete for factors
involved in membrane translocation important for production
of NarK, and thus may be a particularly poor choice for
membrane protein production. In many cases we observed clear
population bias eﬀects by simple visual inspection on agar
plates, and the diﬀerent robustness of the T7- and the K1F-
based bacterial hosts highlights the value of adding promoter
tuning as an extra dimension in the cell factory performance
screen. These observations could be supported by an array of
omics studies leading to a highly informed theoretical
framework for rational cell factory design.
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Materials and Methods 
Strains, media and plasmids 
Escherichia coli NEB5 (New England Biolabs, Ipswich, MA, USA) was used for 
propagation of plasmids, backbone swapping optimization and as a general cloning 
host except when E. coli DB3.1 (Thermo Fisher Scientific, Invitrogen, Waltham, MA, 
USA) was used for handling of ccdB-containing plasmids. NEB5::T7* and 
NEB5::K1F1 were used for -carotene production. SOC media was used as a 
recovery media after transformation. Bacteria were propagated in Luria-Bertani (LB) 
liquid media or agar plates supplemented with ampicillin (100 g/ml), kanamycin (50 
g/ml), chloramphenicol (50 g/ml), spectinomycin (50 g/ml), tetracycline (10 
g/ml), or gentamycin (10 g/ml) when required. In most cases LB media was used 
for liquid cultures except for carotenoid production assessment that was accomplished 
in 2×YT media supplemented with 0.5% glycerol.  
 
Molecular biology reagents 
T4 DNA ligase and restriction enzymes were purchased from Thermo Fischer 
Scientific (Waltham, MA, USA). Nicking enzymes were purchased from New 
England Biolabs (Ipswich, MA, USA). Plasmids were isolated using the QIAprep 
Spin Miniprep Kit (Qiagen, Hilden, Germany). PCR products were purified using a 
PureLink™ Quick Gel Extraction and PCR Purification Combo Kit (Life 
Technologies, Foster City, USA). Buffers for PCR and cloning reactions were 
 
purchased from Agilent Technologies (Santa Clara, CA, USA) and Thermo Fischer 
Scientific (Wilmington, USA). PCR was performed with the proofreading PfuX7 
polymerase as previously described.3 
 
Plasmid constructions 
SEVA linker sequences (version #1, see Supporting Information Figure S3) were 
introduced into pACYCDuet-1 and pCDFDuet-1 (for references to plasmids see 
Supporting Information Table S2) by amplifying the backbones with oligonucleotides 
#1 and #2 (for numbering and sequences of oligonucleotides see Supporting 
Information Table S1), gfp from pETDuet-1-gfp with the oligonucleotides #3 and #4 
and lacZ  from pBluescript II KS (+) with oligonucleotides #5 and #6, followed by 
assembly by uracil excision as described previously.1, 2 This created pACYC-sl1- gfp 
and pCDF-sl1-gfp. 
The ccdB gene was amplified from pOSIP-KT using oligonucleotides #7 and 
#8 and mixed with a pACYC-sl1 fragment obtained from Nb.BtsI-digested pACYC-
sl1-gfp creating pACYC-sl1-ccdB upon transformation into E. coli.  
pCDF-sl2-gfp was constructed by amplifying the vector backbone and gfp 
insert from pCDF-sl1-gfp with oligonucleotides #9 and #10,  and #11 and #12, 
respectively,  treating the PCR products with Nb.BtsI and transforming the fragments 
into E. coli. pACYC-sl2-ccdB was similarly obtained by combining Nb.BtsI-digested 
pACYC-sl1-ccdB with a backbone fragment amplified from pACYC-sl1-ccdB with 
oligonucleotides #9 and #10.  
pCDF-sl3-gfp and pACYC-sl3-ccdB were created by amplifying the 
corresponding sl2 versions with oligonucleotides #13 and #14, gfp with #15 and #16, 
and ccdB with #17 and #18, followed by Nt.BbvCI-treatment and transformation. 
 
pCDF-sl4-gfp and pACYC-sl4-ccdB were created by amplifying the 
corresponding sl2 versions with  the oligonucleotides #19 and #20, gfp with #21 and 
#22, and ccdB with #23 and #24 followed by uracil excision cloning.  
pSEVAXX-sl3-ccdB series was constructed by combining five origins of 
replication (pBBR1; #3, p15A; #6, pSC101; #7, pUC; #8, pBR322/ROP; #9), 
prepared by digestion with PacI and PshAI from the corresponding parts in the 
pSEVA collection, and six antibiotic resistance markers (ampicillin; #1, kanamycin; 
#2, chloramphenicol; #3, spectinomycin; #4, tetracycline; #5, gentamycin; #6), 
prepared by digestion with PshAI and SpeI from the corresponding parts in the 
pSEVA collection, with the sl3-ccdB cargo isolated after digestion by PacI and SpeI 
from pACYC-sl3-ccdB.  
The -carotene biosynthetic pathway was introduced into pACYC-sl3 by 
SEVA cloning (see below) after amplifying the crtEBIY operon from pSIJ31B with 
the oligonucleotides #25 and #26, creating pACYC-sl3-T7-crtEBIY. Combining 
pACYC-sl3-T7-crtEBIY with the pSEVAXX-sl3-ccdB series as described below 
created the pSEVAXX-sl3-T7-crtEBIY series.  
The T7-narK-gfp cargo was amplified from pET28a-narKWTP7-6 using 
oligonucleotides #29 and #30, and mixed with a pSEVAXX-sl3 backbone amplified 
with oligonucleotides #27 and #28 followed by uracil excision cloning. Combining 
the initial pSEVAXX-sl3-T7-narK-gfp clone with the pSEVAXX-sl3-ccdB series 
created the complete pSEVAXX-sl3- T7-narK-gfp series.  
 
Nicking enzyme mediated one-tube backbone exchange (SEVA cloning) 
0.06 pmol of each plasmid were added to a 10 or 20 @l total reaction volume 
containing CutSmart® buffer (New England Biolabs, Ipswich, MA, USA) and five 
 
units of Nt.BbvCI. Mixtures were kept at 37°C for 1 h, followed by 25°C for 15 min, 
10°C for 10 min, then incubation at 0°C using a C1000 TouchTM Thermal Cycler 
(Bio-Rad, Hercules, CA, USA). 2.5 U of T4 DNA ligase and buffer were added, 
followed by incubation at room temperature for 15 min and storage on ice prior to 
transformation.  
 
Gibson assembly- and uracil excision-based backbone exchange 
The GFP cargo was PCR amplified from pCDF-sl3-gfp using the oligonucleotides 
#31 and #32 for Gibson assembly and #35 and #36 for uracil excision; and the 
backbone was amplified from pACYC-sl3-ccdB using the oligonucleotides #33 and 
#34 (Gibson) or #37 and #38 (uracil excision). After PCR, DpnI treatment was done 
at 37°C for 40 min followed by gel purification. Insert and vector ratio of 2:1 was 
applied for both methods. Gibson assembly was performed with 2X Gibson Assembly 
Master Mix (New England Biolabs, Ipswich, MA, USA) following the manufacturer´s 
instructions. Assembly by uracil excision was as described previously.1, 2 
 
Production and relative quantification of -carotene 
The NEB5T7* and NEB5K1F strains1 were used to compare -carotene 
productivity in the pSEVA-crtEBIY series. Corresponding strains with the pathway 
integrated in one copy on the genome (NEB5T7*::EBIY and NEB5K1F::EBIY) 
were used as reference strains.1 Cells were grown in 2×YT media supplemented with 
0.5% glycerol at 30°C for 72 hours with 300 rpm. 1 ml of each culture was harvested 
by centrifugation at 13000 rpm for 5 min. After discarding the supernatant, cells were 
washed once with 1 ml of water. 1 ml of acetone was added and the pellets re-
suspended vigorously by vortexing, followed by incubation at 55°C for 20 min at 
 
1000 rpm using a tabletop shaker. The remaining cell debris were removed by 
centrifugation (13000 rpm, 5 min) and absorbance at 453 nm was measured in a UV-
1600PC spectrophotometer (VWR International, Radnor, PA, USA) on 500 El extract 
using a quartz cuvette. The equation for calculating -carotene production titers is 
   

 where A is the UV/Vis absorbance at 453 nm and   is the specific 
absorption coefficient ( , -carotene=2503).4 
 
Production and quantification of NarK-GFP  
The pSEVAXX-sl3- T7-narK-gfp series was transformed into BL21 (DE3) (Novagen, 
Madison, WI, USA) using a standard protocol. Overnight cultures were prepared by 
inoculating a single colony in 800 EL of LB liquid media containing the different 
pSEVA-defined antibiotics (100 Eg/ml ampicillin; 50 Eg/ml kanamycin; 34 Eg/ml 
chloramphenicol; 50 Eg/ml spectinomycin; 10 Eg/ml tetracycline; 10 Eg/ml 
gentamycin) in 96-deep well plates at 37 °C and 300 rpm in an Innova 44 incubator 
(Thermo Scientific, Waltham, MA, USA). For expression measurements, overnight 
cultures were back-diluted 1:50 in 3 ml LB media containing the different antibiotics 
in 24-well plates at 37 °C and 300 rpm. When exponential phase (an OD600 of 
approximately 0.5) was reached, expression was induced by addition of 1 mM IPTG 
and incubated at 25 °C and 300 rpm for 2 hours. Subsequently, 1 ml of culture was 
harvested at 2270 x g for 20 min, resuspended in a buffer (50 mM TrisHCl (pH 8.0), 
200 mM NaCl, and 15 mM EDTA) and incubated for 2 hours at room temperature. 
Fluorescence was measured in a 96-well plate in a Synergy™ Mx plate reader 
(BioTek) (excitation wavelength 485 nm; emission wavelength 512 nm). The amount 
of protein produced was estimated from a GFP standard curve. The standard curve 
was obtained from purified GFP mixed with BL21 (DE3) cells to account for 
 
quenching effects. 22 h after induction the remaining culture was harvested, 
resuspended in buffer, incubated for 2 hours and fluorescence measured as described 
above. 
  
 
  
 
Figure S1. Illustration of the Standard European Vector Architecture (SEVA) system 
and the relationship to the SEVA linkers and plasmids described here. Left panel: In 
the original SEVA system, rare restriction sites flank the three basic components: 
origins of replication, antibiotic selection markers and the cargo. This basic design 
enables exchange of the basic components using classical restriction enzyme 
molecular cloning. Right panel: The new SEVA linkers enable simple, one-pot 
backbone shuffling by introducing two multifunctional linker sequences (highlighted 
in yellow and orange color) flanking the cargo in the SEVA system. In this example, 
the ccdB counterselection marker is the cargo. Any cargo that is flanked by SEVA 
linkers can be converted to the SEVA system by utilizing the PacI and SpeI 
restriction sites, but also by a range of other molecular cloning technologies (see main 
text). The SEVA linkers violate the basic SEVA design rules by reusing the AscI and 
FseI sites (highlighted in blue and red font). 
  
 
  
 
Figure S2. Demonstration of amplification and reassembly of SEVA linker flanked 
cargo and backbone with Gibson assembly and uracil excision cloning. (a) Agarose 
gel showing PCR amplified cargoes and backbones compatible with Gibson assembly 
or uracil excision cloning. In the cargo, SEVA linkers flanked a transcriptional unit (a 
leaky Ptrc promoter driving expression of gfp). For details on the protocol see 
Materials and Methods. (b) PCR-amplified cargo and backbone was reassembled with 
Gibson and uracil excision cloning and plated on agar plates supplemented with the 
antibiotic corresponding to the backbone selection marker. Green fluorescent colonies 
demonstrate the presence of the cargo. 
 
 
 
 
Figure S3. Exchange of DNA fragments using four Nt.BbvCI- nicking enzyme- sites 
in the SEVA linkers. Yellow and orange boxes mark the four Nt.BbvCI recognition 
sites. The two three-nucleotide spacers between the two double nicking sites are 
different from each other, thereby ensuring specificity and directionality in the parts 
exchange. Any cargo (light blue box) of choice can replace the ccdB (red box) 
counterselection marker. 
 
 
 
 
Figure S4. Demonstration of parts exchange between two plasmids that contain 
SEVA linkers. (a) Illustration of a gfp expressing SEVA linker cargo in a plasmid that 
confers chloramphenicol resistance, mixed with a lacZ expressing SEVA linker 
cargo in a plasmid conferring spectinomycin resistance, leading to four different 
recombinant plasmids. (b) Left panel: The two different plasmids were transformed 
into NEB5 and plated on LB agar supplemented with X-gal combined with 
spectinomycin or chloramphenicol. Right panel: The two plasmids were mixed with 
the nicking enzyme Nb.BtsI, transformed into NEB5 and plated on LB X-gal agar. 
 
 
 
Figure S5. Different types of nicking enzyme-based linkers that were tested for 
cloning efficiency and accuracy. Version #2 outperforms version #1 in simplicity, but 
the Nb.BtsI-based designs generally performed poorly, probably due to the frequent 
occurrence of the six-nucleotide recognition sites outside the SEVA linkers. Version 
#4 likewise performed poorly, probably because the single-strand overhangs formed 
by the Nt.BspQI sites were too stable. Version #3 clearly outperformed the other 
designs in terms of cloning efficiency and accuracy and was the preferred choice for 
the SEVA linkers. 
  
 
Table S1. Oligonucleotides used in this study 
 
No. NAME SEQUENCE 
1 Duet-sl1-rev ATCGCGAUCACTGCCGCGCGCGCGTCGACGGGCGCGCCGCGGCCGCTTAATTAACAAAATTATTTCTACAGGGGAATTGTTATCCGCTC 
2 Duet-sl1-fwd AGAGCGAUCGCACTCACTGCGGCCGGCCCCTGCAGGCGCCGGCGACTAGTCCTAGGCTGCTGCCACCGCTG 
3 Sl1-PtrcGFP_fwd ATCGCGAUCGCTCTTCATATATCGCGATCACTGCTTGACAATTAATCATCCGGCTCGTATAATG 
4 Sl1-PtrcGFP_rev ATCGCTCUTCATATATCGCGATCACTGCTTATTTGTAGAGCTCATCCATGCCATGTG 
5 Sl1-lacZa_fwd ATCGCGAUCGCTCTTCATATATCGCGATCACTGCACCAGTGGNTCATCTCCAAGCAGTGGTTCGCGCAACGCAATTAATGTGAG 
6 Sl1-lacZa_rev AGTGCGAUCGCTCTTCATATAGTGCGATCACTGCACCAGTGCTACCTCCTGAACCAC 
7 Sl1-ccdB_fwd ATC GCG AUC GCT CTT CAT ATA TCG CGA TCA CTG CTA CTA AAA GCC AGA TAA CAG TAT GCG TAT 
8 Sl1-ccdB_rev AGT GCG AUC GCT CTT CAT ATA GTG CGA TCA CTG CCG GGT TAT TAT ATT CCC CAG AAC ATC AG 
9 Nb.BtsI_SL_F (vector) ATCGCactCACTGCGGCCGGCCCCTG 
10 Nb.BtsI_SL_R (vector) ATCGCgatCACTGCCGCGCGCGCGTC 
11 Nb.BtsI_PtrcGFP_F ATCGCGATCACTGCTTGACAATTAATCATCCGGCTCGTATAATG 
12 Nb.BtsI_PtrcGFP_R AGTGCGATCACTGCTTATTTGTAGAGCTCATCCATGCCATGTG 
13 Nt.BbvCI_V_F GGTCGCCTCAGCGGCCGGCCCCTGCAGGCG 
14 Nt.BbvCI_V_R GGTATCCTCAGCCGCGCGCGCGTCGACGGG 
15 Nt.BbvCI_GFP_F GGATACCTCAGCTTGACAATTAATCATCCGGC 
16 Nt.BbvCI_GFP_R GGCGACCTCAGCTTATTTGTAGAGCTCATCCATGC 
17 Nt.BbvCI_CCDB_F GGATACCTCAGCTACTAAAAGCCAGATAACAGTATGC 
18 Nt.BbvCI_CCDB_R GGCGACCTCAGCCGGGTTATTATATTCCCCAG 
19 Nt.BspQ1_V_R_U AGA AGA GCT CTT CUC GCG CGC GCG TCG ACG GG 
20 Nt.BspQ1_V_F_U  AGAAGAGCGCTCTTCUGGCCGGCCCCTGCAGGCG 
21 Nt.BspQ1_GFP_F_U  AGAAGAGCTCTTCUTTGACAATTAATCATCCGGC 
22 Nt.BspQ1_GFP_R_U  AGA AGA GCG CTC TTC UTT ATT TGT AGA GCT CAT CCA TGC 
23 Nt.BspQ1_ccdB_F_U  AGAAGAGCTCTTCUtactaaaagccagataacagtatgc 
24 Nt.BspQ1_ccdB_R_U  AGA AGA GCG CTC TTC UCG GGT TAT TAT ATT CCC CAG AAC ATC AG 
25 Nt.BbvCI_EBIY_F GGATACCTCAGCGGATCTCGACGCTCTCCC 
26 Nt.BbvCI_EBIY_R GGCGACCTCAGCGATTATGCGG 
27 SL3-backbone_rev AGGTATCCUCAGCCGCGCG 
28 SL3-backbone_fwd AGCTGAGGUCGCCTCAGC 
29 NarK-sl3_fwd AGGATACCUCAGCTAATACGACTCACTATAGGG 
30 NarK-sl3_rev ACCTCAGCUCAGTGGTGGTGG 
31 SL-Gibson_ifwd TTAATTAAGCGGCCGCGGCGCGCCCGTCGA 
32 SL-Gibson_irev ACTAGTCGCCGGCGCCTGCAGGGGCCGGCC 
33 SL-Gibson_bbfwd GGCCGGCCCCTGCAGGCGCCGGCGACTAGT 
34 SL-Gibson_bbrev TCGACGGGCGCGCCGCGGCCGCTTAATTAA 
35 SL3m-Ptrc_U_F AGGATACCUCAGCTTGACAATTAATC 
36 SL3m-GFP_U_R ACCTCAGCUTATTTGTAGAGCTC 
37 pCDF_BB_U_F AGCTGAGGUCGCCTCAGC 
38 pCDF_BB_U_R AGGTATCCUCAGCCGCGCG 
 
 
 
 
 
Table S2. Strains and plasmids used in this study 
 
Strain/plasmid Property Source/Reference 
Strains   
E. coli NEB5 fhuA2 (argF-lacZ)U169 phoA glnV44 80 (lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
NEB 
E. coli DB3.1 F- gyrA462 endA1 glnV44 (sr1-recA) mcrB mrr 
hsdS20(rB-, mB-) ara14 galK2 lacY1 proA2 rpsL20(Smr) 
xyl5 leu mtl1 
Thermo Fisher 
Scientific 
NEB5::T7* NEB5 with a T7* RNA polymerase integrated  (1) 
NEB5::K1F NEB5 with a T7*(K1F) RNA polymerase integrated (1) 
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB- mB-) (DE3 [lacI lacUV5-
T7 gene 1 ind1 sam7 nin5]) 
Novagen 
   
Plasmids   
pCDFDuet-1 Cloning and expression vector, SpR Novagen 
pACYCDuet-1 Cloning and expression vector, CmR Novagen 
pETDuet-1-gfp Constitutively expressed GFP, AmpR (1) 
pBluescript II 
KS(+) 
lacZa expressed from lac promoter Agilent 
Technology 
pCDF-sl1- lacZa  lacZ fragment flanked by SEVA linker ver1, SpR, 
CloDF13 origin from pCDFDuet-1  
This study 
pACYC-sl1-gfp gfp flanked by SEVA linker ver1, CmR, p15A origin from 
pACYCDuet-1 
This study 
   
pCDF-sl2-gfp gfp flanked by SEVA linker ver2, SpR, CloDF13 origin 
from pCDFDuet-1 
This study 
pACYC-sl2-
ccdB 
ccdB flanked by SEVA linker ver2, CmR, p15A origin 
from pACYCDuet-1 
This study 
pCDF-sl3- gfp gfp flanked by SEVA linker ver3, SpR, CloDF13 origin 
from pCDFDuet-1 
This study 
pACYC-sl3-
ccdB 
ccdB flanked by SEVA linker ver3, CmR, p15A origin 
from pACYCDuet-1 
This study 
pCDF-sl4- gfp gfp flanked by SEVA linker ver4, SpR, CloDF13 origin 
from pCDFDuet-1 
This study 
pACYC-sl4-
ccdB 
ccdB flanked by SEVA linker ver4, CmR, p15A origin 
from pACYCDuet-1 
This study 
pSIJ31B P. ananatis crtEBIY operon, SpR, CloDF13 origin Unpublished 
pOSIP-KT P21 Integration module, ccdB, KmR, pUC origin  (5) 
pET28a-
narKWTP7-6 P7-6 
narK-gfp with T7 promoter, KmR, pBR322/ROP origin (6) 
pSEVA13-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pBBR1 origin This study 
pSEVA16-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, p15A origin This study 
pSEVA17-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pSC101 origin This study 
pSEVA18-sl3-
ccdB 
ccdB flanked by SEVA linkers, AmpR, pUC origin This study 
pSEVA19-sl3-
ccdB 
ccdB flanked by SEVAlinkers, AmpR, pBR322/ROP origin This study 
pSEVA23-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pBBR1 origin This study 
pSEVA26-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, p15A origin This study 
pSEVA27-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pSC101 origin This study 
pSEVA28-sl3-
ccdB 
ccdB flanked by SEVA linkers, KmR, pUC origin This study 
pSEVA29-sl3- ccdB flanked by SEVA linkers, KmR, pBR322/ROP origin This study 
 
ccdB 
pSEVA33-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pBBR1 origin This study 
pSEVA36-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, p15A origin This study 
pSEVA37-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pSC101 origin This study 
pSEVA38-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pUC origin This study 
pSEVA39-sl3-
ccdB 
ccdB flanked by SEVA linkers, CmR, pBR322/ROP origin This study 
pSEVA43-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pBBR1 origin This study 
pSEVA46-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, p15A origin This study 
pSEVA47-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pSC101 origin This study 
pSEVA48-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pUC origin This study 
pSEVA49-sl3-
ccdB 
ccdB flanked by SEVA linkers, SpR, pBR322/ROP origin This study 
pSEVA53-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pBBR1 origin This study 
pSEVA56-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, p15A origin This study 
pSEVA57-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pSC101 origin This study 
pSEVA58-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pUC origin This study 
pSEVA59-sl3-
ccdB 
ccdB flanked by SEVA linkers, TetR, pBR322/ROP origin This study 
pSEVA63-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pBBR1 origin This study 
pSEVA66-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, p15A origin This study 
pSEVA67-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pSC101 origin This study 
pSEVA68-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pUC origin This study 
pSEVA69-sl3-
ccdB 
ccdB flanked by SEVA linkers, GmR, pBR322/ROP origin This study 
pSEVA13-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, pBBR1 
origin 
This study 
pSEVA16-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, p15A 
origin 
This study 
pSEVA17-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, pSC101 
origin 
This study 
pSEVA19-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, AmpR, 
pBR322/ROP origin 
This study 
pSEVA23-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, pBBR1 
origin 
This study 
pSEVA26-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, p15A 
origin 
This study 
pSEVA27-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, pSC101 
origin 
This study 
pSEVA29-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, KmR, 
pBR322/ROP origin 
This study 
pSEVA33-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, pBBR1 
origin 
This study 
pSEVA36-sl3- crtEBIY operon flanked by SEVA linkers, CmR, p15A This study 
 
T7-crtEBIY origin 
pSEVA37-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, pSC101 
origin 
This study 
pSEVA39-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, CmR, 
pBR322/ROP origin 
This study 
pSEVA43-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, pBBR1 
origin 
This study 
pSEVA46-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, p15A 
origin 
This study 
pSEVA47-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, pSC101 
origin 
This study 
pSEVA49-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, SpR, 
pBR322/ROP origin 
This study 
pSEVA53-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, pBBR1 
origin 
This study 
pSEVA56-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, p15A 
origin 
This study 
pSEVA57-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, pSC101 
origin 
This study 
pSEVA59-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, TetR, 
pBR322/ROP origin 
This study 
pSEVA63-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, pBBR1 
origin 
This study 
pSEVA66-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, p15A 
origin 
This study 
pSEVA67-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, pSC101 
origin 
This study 
pSEVA69-sl3-
T7-crtEBIY 
crtEBIY operon flanked by SEVA linkers, GmR, 
pBR322/ROP origin 
This study 
pSEVA13NarK/
GFP 
narK-gfp flanked by SEVA linkers, AmpR, pBBR1 origin This study 
pSEVA16-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, p15A origin This study 
pSEVA17-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pSC101 origin This study 
pSEVA18-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pUC origin This study 
pSEVA19-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, AmpR, pBR322/ROP 
origin 
This study 
pSEVA23-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pBBR1 origin This study 
pSEVA26-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, p15A origin This study 
pSEVA27-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pSC101 origin This study 
pSEVA28-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pUC origin This study 
pSEVA29-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, KmR, pBR322/ROP 
origin 
This study 
pSEVA33-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pBBR1 origin This study 
pSEVA36-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, p15A origin This study 
pSEVA37-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pSC101 origin This study 
pSEVA38-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pUC origin This study 
pSEVA39-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, CmR, pBR322/ROP 
origin 
This study 
pSEVA43-sl3- narK-gfp flanked by SEVA linkers, SpR, pBBR1 origin This study 
 
T7-narK-gfp 
pSEVA46-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, p15A origin This study 
pSEVA47-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pSC101 origin This study 
pSEVA48-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pUC origin This study 
pSEVA49-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, SpR, pBR322/ROP 
origin 
This study 
pSEVA53 -sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pBBR1 origin This study 
pSEVA56 -sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, p15A origin This study 
pSEVA57-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pSC101 origin This study 
pSEVA58-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pUC origin This study 
pSEVA59-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, TetR, pBR322/ROP 
origin 
This study 
pSEVA63-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pBBR1 origin This study 
pSEVA66-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, p15A origin This study 
pSEVA67-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pSC101 origin This study 
pSEVA68-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pUC origin This study 
pSEVA69-sl3- 
T7-narK-gfp 
narK-gfp flanked by SEVA linkers, GmR, pBR322/ROP 
origin 
This study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table S3. -carotene and NarK production overview 
 
Strain/pSEVA construct Resistance/origin Production (mg/L) 
NEB5::T7*  /genome 1.29 
NEB5::T7*::KmR Km/genome 1.30 
13 Amp/pBBR1 0.64 
16 Amp/p15A 1.56 
17 Amp/pSC101 0.54 
19 Amp/pBR322/ROP 3.69 
23 Km/pBBR1 0.97 
26 Km/p15A 1.37 
27 Km/pSC101 0.61 
29 Km/pBR322/ROP 0.38 
33 Cm/pBBR1 1.24 
36 Cm/p15A 1.70 
37 Cm/pSC101 0.63 
39 Cm/pBR322/ROP 0.31 
43 Sp/pBBR1 1.54 
46 Sp/p15A 1.91 
47 Sp/pSC101 1.03 
49 Sp/pBR322/ROP 0.67 
53 Tet/pBBR1 0.95 
56 Tet/p15A 1.51 
57 Tet/pSC101 0.66 
59 Tet/pBR322/ROP 2.69 
63 Gm/pBBR1 1.72 
66 Gm/p15A 3.16 
67 Gm/pSC101 0.51 
69 Gm/pBR322/ROP 0.59 
NEB5::K1F   
13 Amp/pBBR1 2.58 
16 Amp/p15A 3.15 
17 Amp/pSC101 2.08 
19 Amp/pBR322/ROP 3.03 
23 Km/pBBR1 3.28 
26 Km/p15A 2.72 
27 Km/pSC101 2.33 
29 Km/pBR322/ROP 0.43 
33 Cm/pBBR1 3.46 
36 Cm/p15A 2.97 
37 Cm/pSC101 2.07 
39 Cm/pBR322/ROP 2.36 
43 Sp/pBBR1 3.41 
46 Sp/p15A 3.13 
47 Sp/pSC101 2.11 
49 Sp/pBR322/ROP 1.83 
53 Tet/pBBR1 3.51 
56 Tet/p15A 3.17 
57 Tet/pSC101 1.53 
59 Tet/pBR322/ROP 4.10 
63 Gm/pBBR1 3.31 
66 Gm/p15A 4.15 
67 Gm/pSC101 1.85 
69 Gm/pBR322/ROP 1.73 
BL21 (DE3), 4hr   
13 Amp/pBBR1 9.32 
16 Amp/p15A 11.84 
17 Amp/pSC101 17.21 
18 Amp/pUC 0.64 
19 Amp/pBR322/ROP 19.43 
 
23 Km/pBBR1 5.50 
26 Km/p15A 6.26 
27 Km/pSC101 3.49 
28 Km/pUC 0.21 
29 Km/pBR322/ROP 0.54 
33 Cm/pBBR1 8.76 
36 Cm/p15A 10.46 
37 Cm/pSC101 1.70 
38 Cm/pUC 7.13 
39 Cm/pBR322/ROP 10.91 
43 Sp/pBBR1 9.25 
46 Sp/p15A 9.08 
47 Sp/pSC101 11.34 
48 Sp/pUC 11.79 
49 Sp/pBR322/ROP 1.92 
53 Tet/pBBR1 2.48 
56 Tet/p15A 2.28 
57 Tet/pSC101 4.72 
58 Tet/pUC 0.55 
59 Tet/pBR322/ROP 0.70 
63 Gm/pBBR1 2.52 
66 Gm/p15A 5.61 
67 Gm/pSC101 2.37 
68 Gm/pUC 1.39 
69 Gm/pBR322/ROP 3.77 
BL21 (DE3), 24hr   
13 Amp/pBBR1 24.29 
16 Amp/p15A 26.68 
17 Amp/pSC101 36.69 
18 Amp/pUC 0.95 
19 Amp/pBR322/ROP 21.08 
23 Km/pBBR1 15.94 
26 Km/p15A 35.15 
27 Km/pSC101 11.36 
28 Km/pUC 0.47 
29 Km/pBR322/ROP 0.72 
33 Cm/pBBR1 22.26 
36 Cm/p15A 34.44 
37 Cm/pSC101 2.71 
38 Cm/pUC 0.88 
39 Cm/pBR322/ROP 42.22 
43 Sp/pBBR1 91.58 
46 Sp/p15A 78.48 
47 Sp/pSC101 32.66 
48 Sp/pUC 57.18 
49 Sp/pBR322/ROP 3.16 
53 Tet/pBBR1 9.63 
56 Tet/p15A 9.29 
57 Tet/pSC101 27.03 
58 Tet/pUC 0.75 
59 Tet/pBR322/ROP 0.96 
63 Gm/pBBR1 35.26 
66 Gm/p15A 25.26 
67 Gm/pSC101 5.80 
68 Gm/pUC 5.96 
69 Gm/pBR322/ROP 23.14 
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ABSTRACT 
 
Cytochromes P450 (CYPs) are enzymes that modify several types of compounds, usually by 
substrate mono-oxygenation, and are of biotechnological interest due to their ability to 
perform challenging chemistry. In comparison with the membrane bound eukaryotic CYPs, 
the soluble bacterial CYPs are more stable and easier to express and purify. However, their 
use as biocatalysts in the biotechnological industry has not been fully explored. Marine 
bacteria are emerging as a yet unexplored source of natural products, many of which are 	
dependent on CYP-modifications. We mined 19 genomes of bioactive marine bacteria and 

identified 26 distinct CYP open-reading frames (ORFs). These ORFs were compared to 
previously studied bacterial CYPs to identify their phylogenetic relationships and putative 
functions. Five CYPs were analyzed in more detail and expressed in the model cell factories 
Escherichia coli and Saccharomyces cerevisiae. Expression in yeast confirmed cytoplasmic 
localization of the bacterial CYPs. Furthermore, we showed that codon optimized bacterial 
CYPs were properly folded in yeast. To our knowledge, the present study represents the first 
successful mining for CYPs from marine bacterial genomes in a merger of white and blue 
biotechnology. 
 	
 

Keywords Cytochrome P450 (CYP), Marine bacterial CYPs, Biotechnological potential, 
Yeast expression 
 

 
INTRODUCTION 
 
Cytochromes P450 (CYPs) are a superfamily of enzymes found in many different taxonomic 
groups. These heme-thiolate proteins bind to carbon monoxide exhibiting an absorption 
spectrum at 450 nm, which is the phenomenon responsible for their designation. They use 	
electrons from NAD(P)H to catalyze scission of molecular oxygen and an associated protein, 

the redox partner, to transfer the reducing equivalents to the heme prosthetic group. CYPs 
modify several substrates by mono-oxygenation and this is the most common function of 
these enzymes, although other functions have been described [1,2,3]. 
 
Several natural compounds are synthesized in microorganisms, plants and fungi through a 
plethora of chemical modifications catalyzed by CYPs [3]. Natural product synthesis includes 
several unique chemical reactions, some of which are performed by the associated CYPs. 
Therefore, understanding the mechanisms of action of CYP enzymes, associated with natural 
product synthetic clusters, will allow for catalytic innovation and can be of great use in 	
biotechnological processes [3]. 

 
In Nature, eukaryotic CYPs are often part of membrane-associated multi protein complexes 
and their use as synthetic catalysts at an industrial scale is hampered by this complexity as 
well as their limited stability and activity when isolated [4,5]. Additionally, the requirements 
for a constant supply of NAD(P)H and a redox partner are challenges in establishing CYP-
based biocatalysis. Despite these obstacles, CYPs have been successfully used in industrial 
settings. For example, in yeast, the co-expression of a CYP, its redox partner and cytochrome 
b5 from plants led to high yield production of the antimalarial drug artemisinin [6,7].  
 	
During the last decades, CYPs have received increased attention. Of the 905 total identified 

CYPs in 2009, 30% were of plant origin, but these only represented 11% of total family 
diversity [8]. Remarkably, bacterial CYPs accounted for only 6% of the total number of 	
 
CYPs, but 18% of family diversity [8].  By August 2013, approximately 20,000 CYP 	
enzymes had been identified and catalogued 	
(http://drnelson.uthsc.edu/CytochromeP450.html). 	
 	
In contrast to eukaryotic CYPs, the bacterial CYPs offer several advantages. So far, all 	
identified bacterial CYPs are soluble (in contrast to membrane-bound) enzymes that are faster 	
and more stable catalysts than their eukaryotic counterparts [4]. The bacterial CYPs are 		
usually associated with ferredoxins and ferredoxin reductases, which are used as redox 	

partners [9]. One of the most extensively studied bacterial CYPs is CYP102A1 from Bacillus 	
megaterium, commonly known as BM3 [10]. BM3 is a self-sufficient enzyme, as it is fused 

with a FAD/FMN reductase (differs from ferredoxin reductases since it has a flavin moiety 

instead of iron-sulfur core), and it uses C12-C20 saturated or unsaturated fatty acids as natural 

substrates [11]. For several years, efforts to achieve immobilization, cofactor regeneration and 

development of assays for CYPs have been focused on BM3 [12]. However, the major 

achievements with BM3 are mostly related to protein engineering towards, in particular, 

hydroxylation of BM3-unnatural substrates [5,13,14,15,16,17,18]. Additional efforts have 

been dedicated to engineering other prokaryotic CYPs into enzymes with the capability to 
	
modify a broad range of substrates aiming to exploit their unique ability to perform 


challenging chemistry in biotechnological processes [19].  

 
Soil microorganisms have been successfully explored as sources of bioactive compounds 
used by the pharmaceutical and biotech industries [20], but the use of marine bacteria for 
similar purposes is on the rise [21,22,23]. Marine bacteria are believed to harbor a multitude 
of novel bioactive compounds due to the unique environmental conditions they have adapted 
to, such as high pressure, high salinity, high or low temperature or oligotrophic conditions 
[24,25]. Some of these bioactive compounds are produced by biosynthetic reactions catalyzed 
by CYPs, which are typically encoded in biosynthetic gene clusters [26]. However, there are 	
very few studies on marine CYPs and bioprospecting marine bacteria would likely provide 

 
novel CYPs. In the present study we have mined the genome sequences of several bioactive 
marine bacteria for CYP-encoding genes. Selected candidates were cloned and expressed in 
both E. coli and S. cerevisiae to explore their cellular localization and biotechnological 
potential in these model microbial cell factories. This study also explores the heterogeneity of 
CYP enzymes in marine bacteria and the process of discovering new CYP enzymatic 
functions.  
 
MATERIALS AND METHODS 
Strains and media 	
All strains used for cloning and expression are listed in Table 1. Saccharomyces cerevisiae 

strain PAP1503 was obtained from Per Amstrup Pedersen (Copenhagen University, 
Denmark). Yeast strains were grown either in synthetic complete (SC) drop-out media (0.67% 
Yeast Nitrogen Base with required amino acids from Sigma-Aldrich, St. Louis, MO, USA)) 
or standard yeast peptone dextrose (YPD) medium (1% yeast extract, 2% peptone, 2% 
dextrose from Sigma-Aldrich, St. Louis, MO, USA) for both liquid cultures and agar plates. 
Yeast transformants were selected on SC media without the appropriate selection 
requirements corresponding to the plasmid-encoded auxotrophic markers. Escherichia coli 
strain NEB5 (New England Biolabs, Ipswich, MA, USA) was used for cloning and 
propagation of plasmids. E. coli strain BL21 (DE3) (Novagen, Madison, WI, USA) was used 	
for radioactive labeling studies. Chemically competent cells of NEB5 and BL21 (DE3) were 

prepared as described elsewhere [27]. Competency of the cells was 2.6-3.3 × 107 CFU/Cg 
DNA. Bacteria were propagated on Luria-Bertani (LB) agar plates (Oxoid, Altrincham, UK) 
or liquid 2xYT media (1.6% tryptone, 1% yeast extract from Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with spectinomycin (50 Cg/mL) or ampicillin (100 Cg/mL) when 
required and Phosphate, Ammonium and Selenomethionine (PASM) media for 35S-
methionine labeling of proteins [28]. 35S-methionine was purchased from Perkin Elmer 
(Waltham, Massachusetts, USA). Plasmids were isolated using the NucleoSpin® Plasmid 
QuickPure Kit (Macherey-Nagel, Durën, Germany). 
 
 
Table 1 – Strains and plasmids used in this study 
 	
 
Genomic DNA isolation and sequencing 
High purity genomic DNA was extracted by successive phenol:chloroform:isoamyl-alcohol 
purification steps followed by precipitation with isopropanol, treatment with RNase, and a 
Strains/Plasmids Property Source 
Saccharomyces cerevisiae 
PAP1503 MAT ura3-52 trp1::GAL10-GAL4 lys2-801 leu21 his3200 
pep4::HIS3 prb11.6R can1 GAL 
[29,30]  
PAP1503_P4 PAP1503 transformed with plasmid pEMBLyex4_P4 This study 
PAP1503_P5 PAP1503 transformed with plasmid pEMBLyex4_P5 This study 
PAP1503_P7 PAP1503 transformed with plasmid pEMBLyex4_P7 This study 
PAP1503_P9 PAP1503 transformed with plasmid pEMBLyex4_P9 This study 
PAP1503_P29 PAP1503 transformed with plasmid pEMBLyex4_P29 This study 
PAP1503_BM3 PAP1503 transformed with plasmid pEMBLyex4_BM3 This study 
PAP1503_CYP79A1 PAP1503 transformed with plasmid pEMBLyex4_CYP79A1 This study 
 
Escherichia coli 
NEB5 fhuA2 (argF-lacZ)U169 phoA glnV44 80(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
New England 
Biolabs 
NEB5_P5 NEB5 transformed with plasmid pCDF_P5 This study 
NEB5_P7 NEB5 transformed with plasmid pCDF_P7 This study 
NEB5_P9 NEB5 transformed with plasmid pCDF_P9 This study 
NEB5_P29 NEB5 transformed with plasmid pCDF_P29 This study 
BL21 (DE3) F– ompT gal dcm lon hsdSB(rB- mB-) (DE3 [lacI lacUV5-T7 gene 
1 ind1 sam7 nin5]) 
Novagen 
BL21 (DE3)_P5 BL21 (DE3) transformed with plasmid pCDF_P5 This study 
BL21 (DE3)_P7 BL21 (DE3) transformed with plasmid pCDF_P7 This study 
BL21 (DE3)_P9 BL21 (DE3) transformed with plasmid pCDF_P9 This study 
BL21 (DE3)_P29 BL21 (DE3) transformed with plasmid pCDF_P29 This study 
 
Plasmids 
pEMBLyex4 High copy-number yeast expression vector controlled by the 
galactose-inducible GAL1-CYC1 promoter, 2= origin of 
replication, URA3, leu2-d 
 [31] 
pEMBLyex4_P4 P4 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_P5 P5 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_P7 P7 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_P9 P9 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_P429 P29 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_BM3 BM3 ORF expressed from PGAL1-CYC1 promoter in pEMBLyex4 This study 
pEMBLyex4_CYP79A1 CYP79A1 ORF expressed from PGAL1-CYC1 promoter in 
pEMBLyex4 
This study 
pCDFDuet-1 Cloning and expression vector, SpR Novagen 
pCDF_P5 P5 ORF expressed from PT7 promoter in pCDFDuet-1 This study 
pCDF_P7 P7 ORF expressed from PT7 promoter in pCDFDuet-1 This study 
pCDF_P9 P9 ORF expressed from PT7 promoter in pCDFDuet-1 This study 
pCDF_P29 P29 ORF expressed from PT7 promoter in pCDFDuet-1 This study 
 	
final purification and precipitation step [32]. Quality assessment and quantification of 
genomic DNA was done in 1% agarose gel electrophoresis, NanoDrop Spectrometer (Saveen 
Werner, Sweden), and Qubit 2.0 Analyzer (Invitrogen, United Kingdom). The genomic DNA 
was used as a template for PCR amplification of the genes of interest.  	
 

Bioinformatic analysis 
The strains used in the genome mining (Fig. 1) were isolated during the Danish Galathea 3 
global research expedition (http://www.galathea3.dk/uk) [33] and whole genome sequenced 
[23]. Prediction of cytochrome P450 genes was performed using an annotation and 
homology-based search after RAST genome annotation [34]. Identification of specific 
biosynthetic gene clusters was performed using antiSMASH 2.0 [35] and annotation-based 
analyses [34]. Possible identity of all predicted cytochromes P450 to known proteins was 
done by Basic Local Alignment Search (BLAST) analysis. Membrane protein topology 
predictions were made using the online tools Topcons http://topcons.cbr.su.se/ [36] and G 	
predictor http://dgpred.cbr.su.se/ [37]. An attempt to identify the families of the new CYPs 

was performed using the information in the “cytochrome P450 homepage” [8].  
 
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Figure 1. Overview of the number of identified cytochromes P450 (CYP) in 19 marine 
bacterial genomes. 
Both members of alpha and gamma-proteobacteria were mined for putative CYPs. Strain 
names and numbers are referenced in the vertical axis with the NCBI whole genome sequence 
accession number in brackets. Black bars represent the number of CYPs identified per 
genome. 	
 

PCR, oligonucleotide design and uracil excision cloning  
All oligonucleotides used for PCR amplification were purchased from Integrated DNA 
Technologies (Coralville, IA, USA) and are listed in Table S1. Oligonucleotides were 
designed with melting temperatures (Tm) of approximately 60°C. The uracil excision-specific 
oligonucleotides were designed with U-overhangs of Tm varying from 20 to 30°C. 
Oligonucleotides used for amplification of parts for homologous recombination-based yeast 
DNA assembly were designed with homology arms of >27 bp. DNA amplification and 
assembly in E. coli with uracil excision cloning were accomplished as described previously 
[38,39]. PCR products were purified using a PureLink™ Quick Gel Extraction and PCR 	
Purification Combo Kit (Life Technologies, Foster City, USA). PCR products were quantified 

using a NanoDrop 8000 (Thermo Scientific, Wilmington, USA). 
 	
Plasmids and strains construction 	
All plasmids used for CYP-ORF expression are listed in Table 1. For testing CYP expression 	
in E. coli, PCR products containing CYP-predicted ORF and U-overhangs complementary to 	
the entry vector were cloned in a pCDFDuet-1 plasmid via two-fragment uracil excision 	
cloning. BL21 (DE3) was transformed and assayed as described below (see section 35S-	
methionine labeling of proteins). In order to avoid negative effects of rare codons in S. 	
cerevisiae, the genes were codon optimized using the codon optimization tool from Integrated 		
DNA Technologies and then synthetized as gBlocks™ gene fragments (Integrated DNA 	

Technologies, Coralville, IA, USA). The codon optimized sequences of P4, P5, P7, P9 and 	
 
P29 have been deposited on GenBank with accession numbers KU710259, KU710260, 

KU710261, KU710262, and KU710263, respectively. These codon optimized gene fragments 

were used as PCR templates for assembly in yeast. Three PCR products with long homology 

arms encoding for protein of interest (CYP), GFP (C-terminally fused to a His8 tag) and 

pEMBLyex4 plasmid previously digested with BamHI and HindIII were transformed directly 

into PAP1503 and assembled in yeast by homologous recombination [40]. The resulting 

construct encodes for the protein of interest (CYP) C-terminally fused to GFP with a TEV 

protease cleavage site in between. The newly assembled plasmids were extracted from yeast 
	
and transformed into NEB5 for plasmid amplification. All constructs were confirmed by 


colony PCR and sequencing. 

 
35S-methionine labeling of proteins 
Transcription and translation of cytochrome P450 enzymes in E. coli was confirmed using the 
rifampicin blocking technique and 35S- methionine labeling [41] as described previously [42]. 
 
Assay for overexpression and production of GFP-fusions 
Overexpression of CYP-GFP fusions in S. cerevisiae was performed in strain PAP1503 as 
described elsewhere [40] with minor modifications: synthetic complete (SC) medium was 	
used instead of synthetic minimal (SD) medium. PAP1503 transformants were grown 

overnight (30°C, 200 rpm) in SC supplemented with glucose (20 g/L) without uracil. 
Overnight cultures were used to inoculate SC without uracil and leucine (SC-ura-leu) in a 
1:50 ratio. Cultures were grown at 30°C for 48 hours before they were used to inoculate 250 
mL of SC-ura-leu medium supplemented with glucose (5 g/L) with an initial optical density 
(OD) of 0.05. This was done in triplicate. Cultures were grown at 30°C, 200 rpm until OD 1.0 
before GFP-fusion production was induced by addition of galactose at a final concentration of 
2% (m/v). Cultures were then grown for 24 hours at 20°C with shaking at 200 rpm.  
 
Microscopy 	
 
S. cerevisiae cells were grown as described above (see previous section). Fluorescence of 

CYP-GFP fusions was visualized at 400 x magnification with a DM4000B fluorescence 
microscope from Leica (Wetziar, Germany). CYP79A1 from Sorghum bicolor was used as a 
membrane protein control [43]. 
 
Protein purification and quantification 
Cell pellets from 0.75 L of CYP-GFP producing cultures were resuspended in 30 mL IMAC 
buffer A (50 mM TRIS-HCl pH 7.5, 500 mM NaCl, 20 mM imidazole) supplemented with 1 
tablet/50 mL complete, EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, 
MO, USA) and cells were lysed by three passes at 20.000 psi through an Emulsiflex-C5 	
(Avestin, Ottawa, Canada). After centrifugation for 15 min at 15.000g, the supernatant was 

loaded onto a 5 mL HisTrap FF crude column (GE Healthcare, Buckinghamshire, UK) 
equilibrated with IMAC buffer A. The columns were washed with 10 column volumes of 
IMAC buffer A and the proteins of interest eluted with a 10 column volume gradient of 0-
100% IMAC buffer B (50 mM TRIS-HCl pH 7.5, 500 mM NaCl, 500 mM Imidazole). 
Fractions containing the proteins of interest were identified by SDS-PAGE, pooled and 
concentrated using Amicon Ultra-15 Centrifugal Filters (Millipore, Billerica, Massachusetts, 
USA). The CYP proteins of interest (P4, P5, P7 and P29) were concentrated using a 30 kDa 
cut-off filter, while P9 and BM3 were concentrated using a 10 kDa and 50 kDa cut-off filter, 
respectively. Protein concentrations were measured with a NanoDrop ND-1000 (NanoDrop 	
Technologies, Inc., Wilmington, DE, USA). Samples were kept at 4°C until permanent 

storage at -80°C.  
 
In-gel fluorescence 
In-gel fluorescence of purified GFP-fusions was carried out in a G:Box chemi XT4 (Syngene, 
Cambridge, UK) using Mini-PROTEAN® TGX™ precast gels from Biorad (Hercules, USA) 
and with 465 nm excitation and 535 nm emission. 
 
 
Absorption Spectroscopy 
Absorption spectra of CYP-GFP fusions at 450 nm were recorded with a SLM Aminco DW-	
2000 TM spectrophotometer (Spectronic Instruments, Rochester, NY, USA) as described 

elsewhere [44]. Purified protein-GFP fusions were used in concentrations between 0.07-1.2 
mg/mL in Tris-HCl buffer pH 8.0.  
 
RESULTS 
Mining the genomes of marine bacteria for cytochromes P450 and redox partners 
The genomes of 19 bioactive marine strains, previously identified as secondary metabolite 
producers [23,45,46], were mined for cytochrome P450 (CYP) encoding genes and a total of 
26 putative CYP genes were identified (Table S2). The number of CYPs ranged from zero to 
nine per bacterial genome (Fig. 1). The identified CYP domain-containing open reading 	
frames (ORFs) had GC contents between 39 and 73% and gene sizes from 300 to 1,400 bp 

(Table S2). Members of the alpha-proteobacteria had up to nine CYP-encoding genes, while a 
maximum of two was detected in a single gamma-proteobacterial strain (Fig. 1). CYP genes 
found in the gamma-proteobacteria were associated with putative specific pathways or 
biosynthetic clusters, such as a predicted gamma-butyrolactone biosynthetic cluster, a cluster 
involved in agar degradation or a non-ribosomal peptide/ polyketide synthase (Table 2). 
 
Table 2 - Short-list of putative CYPs to be further studied and their redox partners 
P450 Strain GenBank 
Accession 
Size 
(bp) 
GC 
(%) 
TM 
domains 
Genomic 
context 
CYP family Ferredoxins Ferredoxin 
Reductases 
P4 S3431 KDC54395 1173 41 None 
Agar 
degradation 
CYP236A1 4 2 
P5 S3726 KJZ11492 1209 39 None 
Butyrolactone 
cluster 
CYP107E1 3 1 
P7 S4079 KJZ21287 1176 54 None Exopolymer 
metabolism 
CYP104A2 4 3 
P9 S4493 KJZ30079 312 56 None 
Cobalt-zinc-
cadmium 
resistance 
CYP152B1 2 2 
P29 S4054 KKE82924 1341 39 None NRPS-PKS CYP197A1 3 3 
 
 	
 
The CYP redox-partners in bacteria are usually ferredoxins or flavoprotein reductases [4] and 

in line with this putative ferredoxins and ferredoxin reductases were identified in all the 
nineteen genomes. For CYPs P4 and P7, genes potentially encoding for redox partners were 
identified immediately downstream of the predicted CYP (Table 2). 
 
Features of CYPs 
We used UniProt (Universal Protein Resource), BLAST (Basic Local Alignment Search 
Tool) and the Cytochrome P450 homepage [8] to compare all predicted CYP sequences with 
previously studied CYPs. All the 26 identified CYPs contained cytochrome P450 domains, 
that were also identified by Pfam analyses [47], regardless of their gene size (data not shown). 	
Although sequence conservation is low within this family of enzymes, their general 

topography and structural fold are highly conserved, allowing CYP domain identification [1]. 
Next, we compared the putative CYP protein sequences to known bacterial CYPs using the 	
BLAST server on the Cytochrome P450 homepage (http://blast.uthsc.edu/) [8]. Several of the 	
identified CYPs were conserved within the same species or genus. However, some diversity 	
(with respect to CYP family) was found in CYP sequences across the different genera of 	
studied marine bacteria (Fig. 2). The most similar bacterial CYPs, a recently reported marine 	
CYP (AHA34040) and previously studied CYPs (AAC68886 and ADC79647) are also shown 	
(Fig. 2). 	
 		
 
CYP236A1
 KDC54395
AAC68886
ADC79647
CYP107E1
 KJZ11492
 KJZ21287
CYP104A2
 KJZ30079
CYP152B1
 KKE82924
CYP197A1
AHA34040
100
99
75
100
77
100
98
0.2  	

Figure 2. Phylogenetic tree of the further studied CYPs. 	
The five CYPs selected for further studies (highlighted in bold) shown together with the most 

similar bacterial CYPs, previously studied CYPs (AAC68886 and ADC79647) and a recently 

studied marine CYP (AHA34040). The nodes with bootstrap support of 70 or more are 

indicated (1000 replications). GenBank accession numbers are indicated for CYPs, except for 

the family representatives, where the CYP identification has been used. 

 

Five CYPs were selected for further analyses based on high sequence homology to CYPs 

belonging to different families with previously identified distinct functions, genome 
	
clustering, pathway prediction, and microorganism diversity: one putative CYP from 


Pseudoalteromonas sp., one from Marinomonas sp., one from Loktanella sp., one CYP from 

Paracoccus sp. and finally, one from Pseudoalteromonas luteoviolacea (Table 2). These 
CYPs not only differed in their primary sequences but were also located in distinct genetic 
environments, suggesting their participation in different metabolic reactions. The metabolic 
pathways and specific reactions, including substrate type were predicted using antiSMASH, 
RAST and BLAST analyses. CYPs P5 and P29 are part of two secondary metabolism 
clusters, predicted to be involved in gamma-butyrolactone and non-ribosomal peptide - 
polyketide synthesis, respectively (Table 2). CYPs P4, P7 and P9 are present in genomic 
 
regions related to agar degradation, exopolymer metabolism and cobalt-zinc-cadmium 	
resistance, respectively (Table 2). 

 
Expression of putative CYPs in model cell factories 
To further study the five putative CYPs, all genes were PCR amplified from genomic DNA 
using the oligonucleotides listed in Table S1 and cloned downstream from a phage T7 
promoter (PT7) in the pCDFDuet-1 plasmid. Despite several attempts, we were not able to 
amplify the P4-encoding ORF from the genome of Pseudoalteromonas sp. (S3431). Proper 
transcription and translation in the model bacterium E. coli BL21 (DE3) was monitored using 
35S-methionine labeling of proteins followed by gel electrophoresis (see materials and 
methods). BL21 (DE3) with an empty plasmid was used as negative control. P9 was only 	
produced in very low amount, but full-length proteins were observed for all tested CYPs (Fig. 

S1).  
 
To elucidate whether these putative CYPs would express in another popular model cell 
factory, Saccharomyces cerevisisae, genes codon optimized for this eukaryotic host were 
ordered form a commercial source (see materials and methods). Additionally, we included the 
well studied bacterial CYP, BM3, as a control [10,11]. All five putative marine CYP-
encoding codon optimized DNA fragments and the control were fused with DNA encoding 
GFP and a His8-tag in a pEMBLyex4 plasmid in the S. cerevisiae strain PAP1503 by yeast 
homologous recombination (Fig. 3A). Subsequently the strains were starved for leucine to 	
increase plasmid copy number as described previously [40]. Starved cultures were used as 

inoculum for higher volume cultures and gene expression was then induced with galactose 
since CYP-GFP fusion expression is driven by the CYC1-GAL1 promoter [40]. Expression 
was confirmed by whole cell fluorescence. All CYP-GFP expressing cells appear green under 
the microscope suggesting that all fusions are being produced in yeast, despite the different 
fluorescent intensities observed (Fig. 3B). 
 
 
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 
Figure 3. CYPs production in yeast. 
(A) Schematic representation of the homologous recombination process that allows the 	
pEMBLyex4 backbone plasmid and the DNA parts encoding for CYPs and GFP to be 

assembled in yeast. (B) Imaging of live yeast cells, induced with galactose for 24 hours at 
20°C, producing the different analyzed CYP-GFP fusions P4, P5, P7, P9 and P29, the BM3 
soluble control and the CYP79A1 membrane protein control. (C) SDS-PAGE analysis of 
purified CYP-GFP fusions P4, P5, P7, P9 and P29. The calculated molecular weights of CYP-
GFP fusions are: P4, 71 kDa; P5, 72 kDa; P7, 71 kDa; P9, 38 kDa; P29, 78 kDa. 
 
Cellular localization of bacterial CYPs expressed in S. cerevisiae 
In contrast to bacterial CYPs, the hydrophobic nature of plant CYPs limits their potential in 
biotechnological applications. To explore the cellular localization of the marine bacterial 	
CYPs expressed in yeast we monitored their appearance with a fluorescence microscope (Fig. 

3B). Topology predictions using the online software Topcons (Topcons 
 
http://topcons.cbr.su.se/ [36] and G predictor http://dgpred.cbr.su.se/ [37] identified no N-
terminal transmembrane segments in the CYPs. In line with this, the GFP signal derived from 
the heterologously expressed bacterial CYPs were homogeneously dispersed in the yeast 
cytoplasm, as compared to a plant membrane-bound CYP that localized to the periphery of 
the cells (Fig. 3B). Microscopy also showed that P9 localized in intensely fluorescent spots 
possibly representing misfolded aggregates (Fig. 3B). 
 
Protein integrity and CO spectra 	
To evaluate the stability and integrity of the expressed CYP-GFP fusions, all five putative 

CYPs were purified by affinity using HisTrap columns, and assessed by SDS-PAGE (Fig. 
3C) and in-gel fluorescence (Fig. S2). CYP-GFP fusions appeared to be produced as full-
length fusions (Fig. 3C) with very little free GFP being detected (Fig. S2). In line with the 
microscopy data (Fig. 3B), P4 and P5 fusions were produced in the highest yields – the final 
concentrations being 0.184 and 0.175 mg/mL, respectively. The production levels of P7-GFP 
and P29-GFP were 0.065 and 0.066 mg/mL, respectively. Surprisingly, the concentration of 
P9-GFP was high at 0.151 mg/mL but only very little protein was detected when analyzed by 
SDS-PAGE and in-gel fluorescence (Fig. 3C and Fig. S2). 
 	
Proteins belonging to the P450 family exhibit light absorption maxima at 450 nm when 

correctly incorporated heme is bound to carbon monoxide. Hence, the most widely used 
method for assaying properly folded and active CYPs involves obtaining CO-binding 
difference spectra [48]. With this in mind, we used the purified CYP-GFP fusions to perform 
CO-binding difference spectra using bacterial CYP BM3 as a positive control (Fig. 4A). 
Again, P4 and P5 were well-behaved, exhibiting the characteristic peak at 450 nm confirming 
the CYP family predictions and suggesting that the enzymes are expressed in a correctly 
folded and active form. P7 and P29 were tested, but the CO-binding spectra were 
inconclusive probably due to low protein concentration (Fig. 4D and 4F). The P9 absorption 
 	
spectra (Fig. 4E) showed no peak at all, as expected by the absence of full-length protein and 	
fluorescence (see previous result sections). 

 
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 	
Figure 4. CO spectra different spectra of reduced CYPs. 	
The analyzed CYP-GFP fusions were kept in 10 mM Tris-HCl buffer pH 7.0 and used in 	
protein concentrations of 0.065-0.184 mg/mL. Absorbance was measured ranging from 400 to 	
500 nm wavelength and appearance of the 450 nm characteristic peak (or the 420 nm peak for 	
misfolded CYPs) was assessed for (A) BM3; (B) P4; (C) P5; (D) P7; (E) P9; (F) P29. 	
 	
DISCUSSION 		
CYPs have received attention due to their association with specific and relevant metabolic 	

pathways and their ability to perform challenging chemistry. Many studies have focused on 	
plants that have a high amount of CYPs per genome [3,49,50,51]. Despite their ubiquity and 

diversity, the study and engineering of plant CYPs is facing several challenges. In higher 

organisms, CYPs are membrane associated, representing a major obstacle in expressing and 

purifying this class of enzymes [52]. Consequently, only two crystal structures of plant-

derived CYPs have been published [53,54]. In addition, plant CYPs are less efficient than 

 

their bacterial counterparts [55], meaning that high levels of expression would probably be 

required for effective and fast conversion of substrates.  

 
	
Bacterial CYPs, although present in lower number as compared to numbers in eukaryotes, are 


soluble, more stable and exhibit higher activity [9,55]. Thus, they are easier to engineer, 

overexpress, purify and crystallize [52]; and known structures of bacterial CYPs have been 
used to assemble mammalian CYP structures based on homology modeling [56,57,58]. The 
hydroxylation of camphor by CYP101 (P450cam) in Pseudomonas putida [59] was a major 
breakthrough in the cytochrome P450 field and a few examples of studies on bacterial CYPs 
have been unraveling important functions in the modification of natural compounds, such as 
the antibiotic albaflavenone in S. coelicolor A3(2) [26] or polybrominated aromatic 
compounds in P. luteoviolacea 2ta16 [60]. However, reports of new bacterial CYPs with new 
functions/substrates are still scarce. 	
 

Marine bacteria are ideal sources of novel chemistry since they are understudied and capable 
of performing a wide range of biological processes under environmentally challenging 
conditions [61,62]. Here we present a study on genome mining and expression of bacterial 
CYPs. Although the number of putative CYPs identified in the 19 analyzed genomes was 
only 26, the diversity was considerable, with 19 different CYPs with protein identity lower 
than 40% (Fig. S3). This diversity was also mirrored in their location in distinct genomic 
environments and similarity to different CYP families, suggesting their participation in 
different metabolic reactions. 
 	
The number of ORFs with CYP domains identified in the studied marine bacteria varied from 

zero to nine per genome (Fig. 1). The high number identified for Ruegueria mobilis F1926 
could be due to the poor quality of the genome sequence of this strain, which has more than 
one thousand contigs. Indeed, the four CYPs found in the other R. mobilis strain (S1942) 
suggest the average number of CYPs probably varies between zero and four in these marine 
 
bacteria. The possible wrong annotation of ORFs with CYP domains can explain the poor 
results obtained for the 300 bp-CYP P9 (Fig. 3B and Fig. S1). P9 showed high similarity to 
CYP152B1, which is involved in fatty acid metabolism [63,64]. P9 function is likely different 
from the other selected CYPs. The P4 and P6 CYPs were present in the same genomic 
context, sharing 99,74% of amino acid identity (Fig. S3). These CYPs were found within a 	
predicted agar degradation cluster where several agarases are present, pointing to a function 

in sugar modification. The closest related CYP family identified for these CYPs is CYP236, 
represented by CYP236A1. The latter was shown to have five agarases placed closely to it in 
a 101 kb plasmid (pSD15) from the agar degrading Microscilla sp. PRE1 [65].  
 
AntiSMASH analysis has shown that P5 CYP is part of a predicted gamma-butyrolactone 
biosynthesis cluster in Marinomonas sp. S3726 [23,35]. Gamma-butyrolactone is a building 
block compound used in chemical industry and of great interest in bio-based production 
[66,67,68]. CYP family prediction places P5 in the CYP170 family. CYP170A1 is the family 
representative and it is responsible for the oxidation of the terpenoid epi-isozizaene to 	
albaflavenone in Streptomyces coelicolor A3(2) [61]. CYP170A1 catalyzes a two-step full 

oxidation of epi-isozizaene to albaflavenone, similar to what could be expected for 
conversion of tetrahydrofuran to gamma-butyrolactone by oxidation of an aromatic ring (Fig. 
S4). 
 
The predicted CYP P7 had high similarity to CYP104A2, an Agrobacterium tumefaciens 
CYP responsible for O-demethylation of plant phenolic compounds produced when infected 
with the plant-pathogen [69,70]. Other CYPs from the same CYP104 family are responsible 
for the O-demethylation of guaiacol during the degradation of the lignin polysaccharide [71]. 
The P7-coding gene is located next to predicted fructose transport and capsule polysaccharide 	
export genes, pointing to a possible involvement in O-demethylation of sugars or 

polysaccharides. Sugar modifications might affect cell fitness and create a bias towards low 
producers, which could explain the low concentration of P7 in yeast (Fig. 3B and C). Despite 
 
the inconclusive P7 CO-spectrum, the fact that this ORF clusters in the genome with 
ferredoxins/ferredoxin reductases supports its CYP prediction, as the confirmed P4 CYP 
(Table 2). 
 
According to antiSMASH predictions, P29 is located right next to a NRPS/PKS gene cluster, 
suggesting its role as a tailoring enzyme involved in compound modification(s). Homology 
searches placed it in the CYP197 family, previously identified in Streptomyces and Bacillus 	
species [72,73]. Streptomyces are known for being prominent producers of natural products 

and contain the highest number of structurally characterized CYPs [3]. 
 
All CYPs were successfully expressed in E. coli (Fig. S1) as commonly observed for other 
bacterial CYPs [12]. A growing field aims at introducing chemical modifications, not possible 
with standard organic chemistry [55]. One such example in E. coli is the synthesis of 1,25-
dihydroxyvitamin D3 from vitamin D3, where a bacterial CYP (CYP105A1) from 
Streptomyces griseolus was used [74]. Protein engineering efforts to modify P450cam [75] 
and BM3 [14] for in vivo oxidation of unnatural substrates demonstrate the importance of 
bacterial CYPs, and support the idea that new bacterial CYPs can be engineered to achieve 	
broader specificity for biotechnological applications. Hence, the marine bacterial CYPs 

presented here appear as promising candidates for protein engineering. 
 
Most of the successful commercial and industrially relevant CYP-dependent processes have 
been performed in S. cerevisiae. Production of a myriad of different compounds such as 
hydrocortisone, pregnenolone, amorphadiene (precursor of artemisinic acid), polyketides, 
isoprenoids, steviol components and opiates has been done in yeast, proving its value as a cell 
factory for these types of molecules [6,76,77,78]. Two major advantages of using yeast are a 
well-developed genetic engineering toolbox and a long history of use in the food industry.  
 	
Conclusions 

 
To our knowledge, our work is the first demonstration of marine bacterial CYPs being 
expressed in yeast. This model cell factory offered a convenient assay allowing for cellular 	
localization studies with GFP-fusions that are easily observed under the microscope. We also 	
showed that it is possible, without further optimization besides codon optimization, to 	
successfully express and produce bacterial CYPs in yeast. The stability and integrity of CYP-	
GFP fusions purified from yeast was evaluated by in-gel fluorescence and CO absorption 	
spectra confirming that P4 and P5 are cytochromes P450 - and that they are properly folded in 	
the yeast system (Fig. 4). Future work should focus on the further optimization of P7 and P29 	
expression in yeast.  		
 	

Besides the obvious advantages of unraveling new functions that can be useful in 	
biotechnology and replacing eukaryotic CYPs, this study is a first step towards exploiting the 

full potential of the bacterial CYPs present in marine environments. Future studies will aim at 

identifying the specific function of these enzymes. 

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Supporting information 
Table S1. List of oligonucleotides and plasmids. 
 
 
 
Number Name Sequence 
1 P4_E.coli_fw AGATATACCUATGGCGAAAGTAATATTTATAACCAAAACAAACGA 
2 P4_E.coli_rv ATTATGCGUTTATTTTGATTTAAAGCTAACGTGCAGACTGT 
3 P5_E.coli_fw AGATATACCUATGAGTATCGAGTTGCATAGTAAGTTAAATAGT 
4 P5_E.coli_rv ATTATGCGUTTAGTTAATAACGATAGGTAGGCTATCTGGGC 
5 P7_E.coli_fw AGATATACCUATGCTGGATTTGCCAATCAATGAGAC 
6 P7_E.coli_rv ATTATGCGUTTAGTCGAGATAGACCGGCAGAT 
7 P9_E.coli_fw AGATATACCUATGCTCGACCTCTATGGTACGAAC 
8 P9_E.coli_rv ATTATGCGUATGCTCGACCTCTATGGTACGAAC 
9 P29_E.coli_fw AGATATACCUATGAAGCAAATACCAAAAGTAACCAACAAAG 
10 P29_E.coli_rv ATTATGCGUTTATTGCTCAATTAACTTATTCACTTTCATGACCAAC 
11 pCDF_P450_fw ACGCATAAUGCTTAAGCYGAACAGAAAGTAATCGTATTG 
12 pCDF_P450_rv AGGTATATCUCCTTATTAAAGTTAAACAAAATTATTTCTACAGGGGA
ATTG 
13 Seq_pCDF_fw AGGTTTTGCGCCATTCGATGG 
14 Seq_pCDF_rv CGATTATGCGGCCGTGTACAA 
15 P4_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATT 
ATGACTTCAAAGATTATAGGCGTTAGTGATTTTCC 
16 P4_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCCTTAGACTTAAAAGAGACGT
GCAAGGAA 
17 P5_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATT 
ATGAGTATCGAGTTACATTCAAAGTTG 
18 P5_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCGTTAATAACAATTGGCAAAG
AATCAGGAC 3’ 
19 P7_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATT 
ATGCTAGACCTACCAATTAACGAAAC 
20 P7_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCGTCTAAGTATACTGGTAGAT
TTAACGG 
21 P9_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATT 
ATGTTAGACTTATATGGCACGAACAC 
22 P9_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCATCAAGACAACGTACATTTC
TCATGATAAATC 
23 P29_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATTA
TGAAGCAGATCCCGAAG 
24 P29_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCCTGCTCGATCAACTTGTTAA
CTTTCATAA 
25 BM3_yGFP_fw ACACAAATACACACACTAAATTACCGGATCAATTCTAAGATAATTA
TGACAATTAAAGAAATGCCTCAGCCAAAAACGT 
26 BM3_yGFP_rv AAATTGACTTTGAAAATACAAATTTTCCCCAGCCCACACGTCTTTTG
CGT 
27 CYC-GAL_long_seq_fw TTACTATACTTCTATAGACACGCAAACAC 
28 GFP_seq_rv GTAGCATCACCTTCACCTTC 
29 GFPup_fw GAAAATTTGTATTTTCAAAGTCAATTTTCTAAAGGTGAAGAATTAT 
30 GFPHISdo_rv CTTCAATGCTATCATTTCCTTTGATATTGGATCATCTAATGGTGATGG
TGATGGTGATGGTGTTTGTACAATTCATCCATACCAT 
 
L         WT      P5        P7       P9      P29 
70 kDa 
15 kDa  
44-51 kDa 
11 kDa 
 
Figure S1. Bacterial CYPs expression in E. coli BL21 (DE3) (35S-methionine labeling of 
proteins). 
 
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 	
Figure S2. Bacterial CYP-GFP fusions production in yeast S. cerevisiae (In-gel 

fluorescence). 
 
 
 	
Figure S3. Amino-acid comparison of the 26 marine bacterial CYPs identified in this study. 	
The top quadrant presents the percentage of identity among the CYPs and the lower quadrant 	
the number of differences. 	
 	
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 		
Figure S4. The chemical modifications performed by CYPs. (A) epi-isozizaene to 	

albaflavenone and (B) tetrahydrofuran to gamma-butyrolactone. 	
 	
 
